Download - Author index of abstracts

ELSEVIER Immunopharmacology 49 (2000) 199-2 17

www.elsevier.com/locate/immpharm

Author Index of Abstracts

Abe, M., Shim& N., Shibata, K., Sakata, N., Katsuragi, T., Akatsu, H. and Okada, H., Evaluating a role of complement activation in allergic lung damage induced by repeated inhala- tion of antigen (49) 26

Abrahams, J.P., see Bos, I.G.A.C. (49) 41 Abrahamsen, M.S., see Dalmasso, A.P. (49) 67 Accardo, P., see Amodeo, G. (49) 24 Acker, G., see Kraiczy, P. (49) 75 Affleck, L.J., see Dodd, I. (491 63 Agostoni, A., see Bergamaschini, L. (49) 23 Agostoni, A., see Carugati, A. (49) 27 Agostoni, A., see Gioffrt, D. (49) 27 Agostoni, A., see Gobbo, G. (49) 61 Agostoni, A., see Cugno, M. (49) 62 Aheam, J.M., see Navratil, J.S. (49) 36 Ahearn, J.M., see Liang, H. (49) 58 Akatsu, H., see Abe, M. (49) 26 Akatsu, H., see Dean, Y.D. (49) 41 Alarcon, G., see Moulds, J.M. (49) 29 Aleshin, Yu.N., see Galebskaya, L.V. (49) 23 Alexander, J.J. and Quigg, R.J., Factor H on rodent platelets

functions as the immune adherence receptor (49) 49 Alkimin, M.G.A., see Liberatore Jr., R.D.R. (49) 27 Al Mohanna, F., see Kotwal, G.J. (49) 76 Alves, C.M.O.S., see Marzocchi-Machado, CM. (49) 90 Alving, C.R., see Szebeni, J. (49) 71 Amadei, B., see Caprioli, J. (49) 13 Ambrus, G., see Zavodszky, P. (49) 89 Ames, R.S., Lee, D., Foley, J.J., Tometta, M.A., Bautsch, W.,

Settmacher, B., Klos, A., Sulpizio, A.C., Hieble, J.P., McCaf- ferty, G. and Sarau, H.M., Pharmacology of SB 290157, a selective small molecule antagonist of the C3a receptor (49) 53

Amodeo, G., D’ Amelio, L., Palombo, G., D’Arpa, N., Accardo, P., Mesellis, M. and Brai, M., Plasma soluble CR1 as a prognostic factor in severe burns (49) 24

Amodeo, G., Neri, S., Cicardi, M., Riela, A. and Brai, M., ClINH abuse: whim or necessity (491 61

Anderson, R., see Parent, J.B. (49) 68 Andersson, J., Nilsson Ekdahl, K. and Nilsson, B., Monitoring of

complement activation on a biomaterial surface (49) 96 Andrl, J., Halter, R., Heske, C., Paul, D. and Vogel, C.-W.,

Transgenic mice expressing cobra venom factor (49) 94 And& J., see Bammert, H. (49) 12 Andrl, J., see Wehrhahn, D. (49) 94

Andrews, E., Lassiter, H., Feldhoff, R. and Feldhoff, P., Cytokine regulation of complement secretion by HepG2 cells (49) 19

Andrews, M., see Botto, M. (49) 36 Anker Peterslund, N., see Thiel, S. (49) 85 Antonov, I.V., see Myones, B.L. (49) 97 Arlaud, G., see Gaboriaud, C. (49) 33 Arlaud, G.J., see Tacnet, P. (49) 16 Arlaud, G.J., see Rossi, V. (49) 17 Arlaud, G.J., see Thielens, N. (49) 87 Amett, F.C., see Rupert, K.L. (49) 29 Arora, M., Arora, R., Das, N. and Srivastava, L.M., Expression of

complement regulatory proteins in idiopathic focal segmental glomerulosclerosis (49) 28

Arora, R., see Arora, M. (49) 28 Atkinson, J., see Liszewski, M.K. (49) 54 Atkinson, J.P., see Gioffre, D. (49) 27 Atkinson, J.P., see Mallin, R. (49) 46 Atkinson, J.P., see Smith, B.O. (49) 46 Atkinson, J.P., see Krych-Godberg, M. (49) 62 Atkinson, J.P., see Brodbeck, W.G. (49) 65 Atkinson, J.P., see Kemper, C. (49) 66 Atkinson, J.P., see Moulds, J.M. (49) 73 Atkinson, J.P., see Kallstrom, H. (49) 75 Ayub, S., see Sivasankar, B. (49) 28 Ayub, S., Sharma, M., Sivasankar, B., Katyal, M. and Das, N.,

Modulation of serum complement and macrophage activation by organophosphate insecticide malation (49) 48

Azzolini, A.E.C.S., see Marzocchi-Machado, CM. (49) 90

Badea, T., Niculescu, F., Soane, L., Shin, M.L. and Rus, H., Molecular cloning and expression of human RGC-32, a novel gene induced by complement and involved in cdc2 activation (49) 93

Badea, T., see Niculescu, F. (49) 93 Bajtay, Zs., see Erdei, A. (49) 84 Baker, L., see Loveland, B.E. (49) 66 Bala Subramanian, V., see Liszewski, M.K. (49) 54 Baldwin, I., see Loveland, B.E. (49) 66 Bally, I., see Gaboriaud, C. (49) 33 Bally, I., see Rossi, V. (49) 17 Bamber, L., see Dodd, I. (49) 63 Bammert, H., Kunze, B., Fritzinger, D.C., Bredehorst, R., And@

J. and Vogel, C.-W., Initial characterization of the cobra venom factor gene (49) 12

200 Aufhor Index of Abstracts

Banki, Z., see Erdei, A. (49) 84 Bao, L., see Kang, H.J. (49) 49 Baranyi, L., see Szebeni, J. (49) 71 Barbashov, S.F., see Ghiran, I. (49) 86 Barbosa, S.F.C., see Liberatore Jr., R.D.R. (49) 27 Barel, M. and Frade, R., Characterization of the ~95 cellular

component phosphorylated on tyrosine after activation of the C3d/Epstein-Barr virus receptor (gpl40, CR2, CD211 on human B lymphocytes (49150

Bare], M.. see Le Romancer, M. (491 50 Barenholz, Y., see Szebeni, I. (49) 71 Barilla-La Barca, M.L., see Gioffre, D. (49) 27 Barlow, P., see Liszewski, M.K. (491 54 Barlow, P., see Kotwal, G.J. (49) 76 Barlow, P.N., see Mallin, R. (491 46 Barlow, P.N., see Smith, B.O. (49) 46 Barlow, P.N., see Herbert, A.P. (49) 6.5 Barnum, S., see Campos-Torres, A. (49) 48 Barrington, R.A., Zafari, M., Fischer, M.B., Pozdnyakova, O.O.,

Benjamin, C. and Carroll, M.C., Role of complement and Fey receptors in maintenance of B lymphocyte memory (49) 37

Barrington, R.A., Zhang, M., Pozdnyakova, 0.0. and Carroll, M.C., Complement-ligand requirement for B lymphocyte survival in germinal centers during a primary response (49) 37

Barrington, R.A., see Pozdnyakova, 0.0. (49) 50 Barrington, R.A., see Zhang, M. (491 50 Basheer, S., see Pratt, J.R. (49) 23 Basta, M., In-vitro inhibition of histamine and thromboxane re-

lease from mast cells by high-dose intravenous immunoglobu- lin (IVIG) (49) 94

Bautsch, W., see Dahlke, M. (49) 12 Bautsch, W., see Grove, M. (49) 25 Bautsch, W., see Hawlisch, H. (49) 44 Bautsch, W., see Ames, R.S. (491 53 Bautsch, W., see Settmacher, B. (49) 89 Bellinati-Pires, R., see Liberatore Jr., R.D.R. (49) 27 Bellomo, R., see Loveland, B.E. (491 66 Benjamin, C., see Barrington, R.A. (49) 37 Benson, B.A., see Dalmasso, A.P. (49) 67 Benzing, W.C., see Parent, J.B. (49) 68 Bergamaschini, L., Gobbo, G., Rossi, E., Ponti, A., Gatti, S.,

Caccamo, L., Braidotti, P. and Agostoni, A., Cl-inhibitor potentiates the protective effect of graft preservation solution during cold storage (49) 23

Bergamaschini, L., see Gobbo, G. (49) 61 Bergg?trd, K., Lindahl, G., Dahlback, B. and Blom, A., Bordetella

percussis binds to human C4BP (C4b-binding protein) at a site similar to that used by the natural ligand C4b (491 75

Berggtid, K., see Blom, A.M. (491 74 Bergseth, G., see Mollnes, T.E. (49) 62 Bergseth, G., see Fure, H. (49) 70 Bettinaglio, P.. see Caprioli, J. (49) 13 Bialonski, A., see Meri, T. (491 57 Billington, S.J., see Tambourgi, D.V. (491 19 Birmingham, D., see Moulds. J.M. (491 73 Birmingham, D.J., Liang, G. and Shen, X.-P., CR1 polymor-

phisms associated with SLE (491 29

Birmingham, D.J., Logar, C.M. and Chen, W., Characterization of the human CRl-like transcript (49) 11

Bjorge, L., Matre, R. and Meri, S., Cell cycle analysis of CD59 expression in ovarian cancer cell lines (49) 21

Blackmer, D., see Krych-Godberg, M. (49) 62 Blackmer, D.J., see Kallstrom, H. (49) 75 Blanchong, C.A., see Yung Yu, C. (49) 32 Blazquez, A.B., see Pastor, C. (491 96 Blazquez, A.B., see Vidarte, L. (49) 40 Blok, V.T., see Gelderman, K.A. (49) 21 Blom, A., see Ram, S. (49) 58 Blom, A., see BerggCd, K. (491 75 Blom, A.M., Villoutreix, B.O., Webb, J.H., Berggird, K., Foltyn-

Zadura, A., Lindahl, G. and Dahlback, B., A Cluster of positively charged amino acids at the interface between C4BP CCPl and CCP2 is crucial for binding of C4b and streptococcal proteins (49) 74

Blom, A.M., see Webb, J.H. (49) 96 Blouin, J., see Fremeaux-Bacchi, V. (49) 14 Blouin, J., see Dragon-Durey, M.A. (49) 25 Boackle, S.A., Brown, J.M. and Holers, V.M.. Role of Comple-

ment Receptors Type 1 (CRl/CD35) and Type 2 (CR2/ CD211 in murine SLE (49) 29

Bock, D., see Settmacher, B. (49) 89 Bohana-Kashtan, O., see Fishelson, Z. (49) 97 Booth, CL., see Jack, D.L. (49) 88 Bos, I.G.A.C., Hoedemaeker, P.J., Hack, C.E. and Abrahams,

J.P., A novel 3D model of Cl-Inhibitor based on the crystal structure of 4 intact serpins (49) 41

Botto, M., Taylor, P.R., Carugati, A., Fadok, V., Cook, H.T., Andrews, M., Carroll, M.C., Savill, J., Henson, P. and Wal- port, M.J., A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in GL.o: a mechanism for protection against autoimmunity (49) 36

Botto, M., see Mitchell, D.A. (49) 18 Botto, M., see Pickering, M.C. (49) 18 Botto, M., see Robson, M.G. (491 27 Botto, M., see Robson, M.G. (491 28 Botto, M., see Norsworthy, P.J. (49) 36 Botto, M., see Holt, D.S. (49) 67 Botto, M., see Petty, F. (491 79 Bovin, N.V., see Roos, A. (49) 18 Bowen, F.W., see Soulika, A.M. (491 62 Brade, V., see Kraiczy, P. (49) 57 Brade, V., see Kraiczy, P. (49) 75 Bradley, J., see Harrison, R. (491 63 Bradt, B.M., see Yu, J.X. (49) 7 Bradt, B.M., see Yu, J.X. (491 14 Brai, M., see Amodeo, G. (49) 24 Brai, M., see Amodeo, G. (49) 61 Braidotti, P., see Bergamaschini, L. (49) 23 Brandon, M.R., see Loveland, B.E. (49) 66 Bredehorst, R., see Bammert, H. (491 12 Bredehorst, R., see Wehrhahn, D. (49) 94 Brekke, O.L., see Mollnes, T.E. (49) 62 Brekke, O.L., see Fure, H. (49) 70 Brockman. M.A., see Verschoor. A. (49) 72

Author Index of Abstracts 201

Brodbeck, W.G., Mold, C., Atkinson, J.P. and Medof, M.E., Cicardi, M., see Amodeo, G. (49) 61 Cooperation between decay accelerating factor and membrane Ciganda, M., Willis, A.C., Dalton, J.P. and Diaz, A., Effects on cofactor protein in protecting cells from autologous comple- C3 of the secreted cathepsin L proteinases from the parasite ment attack (49) 65 Fasciola hepatica (49) 74

Brown, J.M., see Boackle, S.A. (491 29 Brunden, K.R., see Gupta-Bansal, R. (49) 68 Brunden, K.R., see Parent, J.B. (49) 68 Butcher, G.A., see Margos, G. (49) 73 Bygrave, A.E., see Holt, D.S. (49) 67 Bygraves, A.E., see Norsworthy, P.J. (49) 36

Circolo, A., see Sekine, H. (49) 28 Clemenza, L. and Isenman, D.E., Structure-guided identification

of C3d residues essential for binding to complement receptor 2 (49) 33

Caccamo, L., see Bergamaschini, L. (49) 23 Calabresi, M., see Schwaeble, W.J. (491 15 Campbell, I., see Campos-Torres, A. (49) 48 Campos-Torres, A., Reiman, R., Martin, B., Campbell, I. and

Barnum, S., Characterization of transgenic mice overexpress- ing the complement anaphylatoxin CSa in the CNS (49) 48

Capey, S., see Van den Berg, C.W. (49) 92 Caprioli, J., Bettinaglio, P., Zipfel, P.F., Vasile, B., Gamba, S.,

Amadei, B., Orisio, S., Remuzzi, G. and Noris, M., Mutations of factor H (HF) in familial hemolytic uremic syndrome (HUS)/thrombotic thrombocytopenic purpura (TTP) (49) 13

Carpenter, P., see Fonseca, M.I. (49) 17 Carroll, M., see Gadjeva, M. (49) 12 Carroll, M.C., see Botto, M. (49) 36 Carroll, M.C., see Barrington, R.A. (49) 37 Carroll, M.C., see Paul, E. (49) 42 Carroll, M.C., see Pozdnyakova, 0.0. (49) 50 Carroll, M.C., see Zhang, M. (49) 50 Carroll, M.C., see Verschoor, A. (491 72 Carroll, M.C., see Pozdnyakova, 0.0. (49) 79 Carroll, M.C., see Xu, Y. (49) 80 Carugati, A., Zingale, L.C., Rivolta, E., Agostoni, A. and Cicardi,

M., Hereditary Cl inhibitor deficiency increases the risk for renal diseases (49) 27

Collan, J., see Harjunpa& A. (49) 20 Collard, CD., Montalto, M. and Stahl, G.L., Endothelial oxidative

stress increases cytokeratin 1 (Kl) expression and human mannose-binding lectin (MBL) deposition (49) 85

Colman, R.W., see Cugno, M. (49) 62 Colten, H., see Sekine, H. (49) 28 Condino-Neto, A., see Leitao, M.F. (49) 14 Connolly, C.C., see Test, ST. (49) 44 Convery, M., see Gupta-Bansal, R. (491 68 Convery, M., see Parent, J.B. (49) 68 Cook, H.T., see Mitchell, D.A. (49) 18 Cook, H.T., see Robson, M.G. (491 27 Cook, H.T., see Robson, M.G. (49) 28 Cook, H.T., see Botto, M. (49) 36 Cooke, H.T., see Pickering, M.C. (49) 18 Cooper, N.R., see Yu, J.X. (491 7 Cooper, N.R., see Yu, J.X. (49) 14 Cozzi, E., see Harrison, R. (49) 63 Cseh, S., see Thielens, N. (491 87 Cseh, S., see Zavodszky, P. (49) 89 Cugno, M., Vecchi, M., Devani, M., Sainz, I., De Franchis, R.,

Agostoni, A. and Colman, R.W., Increased Cl-inhibitor levels and lack of contact system activation in plasma from patients with Crohn’s disease (49) 62

Cui. W., see Liszewski, M.K. (49) 54 Cullinane, M., see Ram, S. (49) 58

Carugati, A., see Botto, M. (49) 36 Casarsa, C., Pausa, M., De Luigi, A., De Simoni, M.G. and

Tedesco, F., Leukocyte migration in the cerebrospinal fluid induced by the injection of the terminal complement complex in the lateral ventricle of rats (49) 17

Chanan-Khan, A.A., see Szebeni, J. (49) 71 Chavez, G., see Harrison, R. (49) 63 Chen, W., see Birmingham, D.J. (49) 11 Chesne, S., see Villiers, C.L. (49) 48 Chevallier, S., see Tacnet, P. (49) 16 Cho, H., see Soane, L. (49) 16 Christensen, T., see Dahl, M.R. (49) 79 Christiansen, D., see Mollnes, T.E. (49) 62 Christiansen, D., see Loveland, B.E. (49) 66 Chronopoulou, E., Ember. J.A., Song, S., Dong, L.P., Ji, X.-D.,

Wang, X.D., Zou, J.-C., Shi, L., Stall, A., Sanderson, S.D., Shih, C.C.-Y. and Morgan, E., C5a- and C3a-receptors de- tected with high affinity monoclonals of rabbit and mouse origin (49) 89

Dabhia, N., see Lassiter, H. (49) 22 Daha, M.R., see Roos, A. (49) 18 Daha, M.R., see Roos, A. (49) 83 Daha, M.R., see Nauta, A.J. (49) 95 Dahl, M.R., Thiel, S., Willis, A.C., Vorup-Jensen, T., Christensen,

T., Petersen, S.V. and Jensenius, J.C., Mannan-binding lectin associated serine protease 3 (MASP-3) a new component of the lectin pathway of complement activation (49) 79

Dahlback, B., see Blom, A.M. (49) 74 Dahlback, B., see Bergglrd, K. (49) 75 Dahlb’ack, B., see Webb, J.H. (49) 96 Dahlback, B., see Ram, S. (49) 58 Dahlke, M., Hawlisch, H., Link, C., Bautsch, W., Klos, A. and

Kohl, J., Selection of a neoepitope specific anti gp C3AdesArg single chain Fv fragment from a combinatoral rabbit antibody library (49) 12

Cicardi, M., see Carugati, A. (49) 27 Cicardi, M., see Gioffre, D. (49) 27

Dalmasso, A.P., Benson, B.A. and Abrahamsen, M.S., Role of CD59 upregulation in endothelial cells protected from complement in a model of xenotransplantation (49) 67

Dalton, J.P., see Ciganda, M. (49) 74 D’Amelio, L., see Amodeo, G. (49) 24

202 Author Index of Abstracts

Danino, D., see Szebeni, J. (49) 71 Dankert, J.R., see Ocana-Morgner, C. (49) 72 D’Arpa, N., see Amodeo, Cl. (49) 24 Das, N., see Arora, M. (491 28 Das, N., see Sivasankar, B. (49) 28 Das, N., see Ayub, S. (49) 48 Dashiell, SM., see Hafer-Macko, C. (49) 16 Davies, A., see Smith, G.P. (49) 53 Davies, A., see Margos, G. (49) 73 Davies, A., see Femie-King, B.A. (49) 74 Davies, K.A., see Robson, M.G. (491 27 Davies, K.A., see Robson, M.G. (491 28 Davis III, A.E., see Zahedi, K. (491 41 Davis III, A.E., see Zahedi, R. (491 61 Dean, Y.D., McGreal, E.P., Akatsu, H., Morgan, B.P. and Gasque,

P., Molecular cloning and tissue expression of the phagocytic complement Clq receptor in rat (49) 41

Dean, Y.D., see McGreal, E.P. (49) 7 De Andrade, R.M.G., see Van den Berg, C.W. (491 95 De Barace, C., see Dragon-Durey, M.A. (49) 25 De Franchis, R., see Cugno, M. (49) 62 De Luigi, A., see Casarsa, C. (49) 17 De Simoni, M.G., see Casarsa, C. (49) 17 De Sousa, M., see Tambourgi, D.V. (491 19 Devani, M., see Cugno, M. (49) 62 Devine, D.V., see Sim, D.S. (491 83 Diaz, A., see Ciganda, M. (49) 74 Diaz, A., see Irigoin, F. (49) 75 Dierich, M.P., see Hess, M.W. (49) 49 Dierich, M.P., see Kacani, L. (491 72 DiScipio, R.G., Sriramarao, P. and Schraufstatter, I., Effect of

complement mediators on eosinophil activation (49) 93 Dissen, E., see Lovik, G. (491 41 Di Stefano, R., see Gobbo, G. (49) 61 Dob6, J., see Zavodszky, P. (49) 89 Dodd, I., Oldroyd, R.G., Powell, S., Affleck, L.J., Bamber, L.,

Gallagher, S., Rowling, P.J.E., Ragnauth, C., Smith, G.P., Pratt, J.R., Sacks, S.H., Linton, S.M., Morgan, B.P. and Smith, R.A.G., Development of a membrane-targeted complement inhibitor for clinical use (49) 63

Dodd, I., see Smith, G.P. (491 53 Dong, J., see Pratt, J.R. (49) 8 Dong, L.P., see Chronopoulou, E. (49) 89 Doumbo, O., see Moulds, J.M. (491 73 Dragon-Durey, M.A., Quartier, P., Fremeaux-Bacchi, V., Blouin,

J., De Barace, C., Prieur, A., Weiss, L. and Fridman, W.H., Molecular basis of a selective and complete Cls deficiency associated with multiple autoimmune diseases of early onset (491 25

Drouin, S.M., Kildsgaard, J., Haviland, J., Jia, H.P., McCray, P.B., Tack, B.F. and Wetsel, R.A., Comparative expression of anaphylatoxin C3a and C5a receptors on lung bronchial ep- ithelial and smooth muscle cells in mouse models of asthma and sepsis (49) 26

Drouin, SM., see Kildsgaard, J. (49) 80 Durey, M.A., see Fremeaux-Bacchi, V. (49) 14 Dzelalija, K., see Rieben, R. (491 71

Ebanks, R.O., see Pan, Q. (49) 54 Edmunds Jr., L.H., see Soulika, A.M. (49) 62 Edwards, Y.J.K., see Hinshelwood, J. (49) 32 Eibel, H., see Friese, M.A. (491 45 Eisenberg, R.A., see Miwa, T. (49) 25 Ekdahl, K.N., Olsson, L. and Nilsson, B., Phosphorylation by a

casein kinase from activated human platelets increases the binding of C3b to CR1 (49) 90

Elkins, C., see Ram, S. (49) 58 Ember, J.A., Windman, S., Luan, F.J., Sasaki, S., Shi, L., Stall,

A., Shih, CC.-Y., Kolb, W.P. and Morgan, E., New neo-epi- tope specific ELISA kits to determine anaphylatoxin C3adesArg

and C5a,,,,, levels in biological fluids (49) 91 Ember, J.A., see Chronopoulou, E. (49) 89 Endo, M., Ohsawa, I., Satomura, A., Hidaka, M., Fujita, T., Ohi,

H., Matsushita, M. and Fujita, T., Mannose binding lectin (MBLJ contributes to complement activation in glomerulonephritis (49) 86

Endo, Y., see Takabashi, M. (49) 3 Endo, Y., see Kuraya, M. (491 11 Endo, Y., see Kenjo, A. (49) 84 Endo, Y., see Matsushita, M. (49) 79 Erdei, A., Bajtay, Zs., J6zsi, M., Banki, Z., Thiel, S. and Thielens,

N., Comparison of binding and functional effects of MBL and Clq on lymphocytes and macrophages (491 84

Erikson, J., see Paul, E. (491 42 Eskelinen, E.L., see Hess, M.W. (49) 49 Espinola, R., see Myones, B.L. (49) 97 Essers, M., see Roos, A. (49) 18 Evans, D., see Spiller, O.B. (49) 67 Evans, D., see Spiller, O.B. (49) 71 Ezekowitz, A., see Liu, H. (49) 84 Ezekowitz, A.R., see Xu, B. (49) 88 Ezekowitz, R.A.B., see Vorup-Jensen, T. (49) 86

Faber-Krol, R., see Roos, A. (49) 83 Fadok, V., see Botto, M. (49) 36 Fadok, V., see Ogden, CA. (49) 40 Fecke, W., Long, J., Richards, A. and Harrison, R., Activation of

porcine endothelial cells by human complement (49) 91 Fedarko, N.S., see Fisher, L.W. (49) 20 Feldhoff, P., Stapp, I., Lassiter, H., S&rock, M. and Feldhoff, R.,

Control of complement expression: the role of cytokines in the regulation of C3 secretion in an H35 cell line (49) 44

Feldhoff, P., see Andrews, E. (491 19 Feldhoff, P., see Lassiter, H. (491 22 Feldhoff, R., see Andrew% E. (49) 19 Feldhoff, R., see Lassiter, H. (49) 22 Feldhoff, R., see Feldhoff, P. (49) 44 Femandez, C., see Irigoin, F. (49) 75 Femie-King, B.A., Seilly, D.J., Davies, A. and Lachmann, P.J.,

The membrane attack complex inhibitor of Streptococcus pyo- genes (SIC) binds preferentially to C567 (49) 74

Ferreira, A., see Irigoin, F. (49) 75 Ferreira, F., see Irigoin, F. (49) 75 Fischer, E., see Nielsen, C.H. (49) 49


Fischer, M.B., see Barrington, R.A. (49) 37 Fischer, S., see Pickering, M.C. (49) 18 Fishelson, Z., Hochman, I. and Bohana-Kashtan, O., Identification

of hsc70 and B-tubulin in L-CIP, the large complement-induced protein complex (49) 97

Fisher, E.M., see Leslie, R.G.Q. (49) 24 Fisher, L.W. and Fedarko, N.S., The SIBLING family of sialopro-

teins bridge factor H to cell surfaces and protect cancer cell lines from lysis by ACP (491 20

Fleming, SD., Rehrig, S.T., Guthridge, J., Holers, V.M., Shea- Donohue, T. and Tsokos, G.C., Crry-Ig, a complement activation inhibitor protects mice from ischemia/reperfusion (IR) induced intestinal injury (49) 22

Fleming, S.D., Rehrig, S.T., Guthridge, J.M., Shea-Donohue, T., Tsokos, G.C. and Holers, V.M., Role of CR2- and CDl9- regulated natural antibodies in intestinal ischemia reperfusion- induced injury (49) 37

Flemme, N., see Grove, M. (49) 25 Fleuren, G.J., see Gelderman, K.A. (49) 21 Florido, M.P.C., see Liberatore Jr., R.D.R. (491 27 Foley, J.J., see Ames, R.S. (491 53 Foltyn-Zadura, A., see Blom, A.M. (49) 74 Fonseca, MI., Carpenter, P., Palmarini, G. and Tenner, A.J.,

Localization of ClqRp in human tissue (491 17 Fontaine, M., see Zhakhov, A. (491 72 Fontecilla, J.C., see Gaboriaud, C. (491 33 Fossati-Jimack, L., see Norsworthy, P.J. (491 36 Frade, R., see Jean, D. (49) 15 Frade, R., see Barel, M. (491 50 Frade, R., see Le Romancer, M. (491 50 Franchini, S., Zarkadis, I.K., Sfyroera, G., Sahu, A. and Lambris,

J.D., Cloning and purification of the rainbow trout fifth component of complement (C51 (491 13

Franchini, S., see Mastellos, D. (491 8 Franchini, S., see Zarkadis, I.K. (491 13 Frank, M.M., see Wagner, E. (49) 61 Frank, M.M., see Jiang, H. (49) 69 Fraser Jr., C.D., see Fung, M. (491 68 FrCmeaux-Bacchi, V., Durey, M.A., Blouin, J. and Kazatchkine,

M.D., Human C6 deficiency has a homogeneous genetic back- ground (49) 14

Fremeaux-Bacchi, V., see Dragon-Durey, M.A. (49) 25 French, A., see Loveland, B.E. (49) 66 Fridman, W.H., see Dragon-Durey, M.A. (49) 25 Friedman, H.M., Saldanha, C., Wang, L., Jiang, M., Grippi, K.,

Lambris, J.D., Lubinski, J. and Penn, II., Herpes simplex virus evasion of complement attack (491 58

Friend, P., see Harrison, R. (491 63 Friese, M., see Sakari Jokiranta, T. (491 44 Friese, M.A., Hellwage, J., Eibel, H., Gordon, D.L., Jokiranta,

T.S., Meri, S. and Zipfel, P.F., Regulation of FHL-I / Reconectin and Factor H transcription and RNA processing (49145

Fritzinger, D.C., see Bammert, H. (491 12 Fritzinger, D.C., see Webrhahn, D. (49) 94 Frosch, M., see Ram, S. (49) 73

Frosch, M., see Jack, D.L. (49) 88 Fujiki, K., see Nakao, M. (49) 12 Fujita, T., see Kuraya, M. (49) 11 Fujita, T., see Jensenius, J.C. (49) 33 Fujita, T., see Kenjo, A. (49) 84 Fujita, T., see Endo, M. (49) 86 Fujita, T., see Matsushita, M. (49) 79 Fujital, T., see Takahashi, M. (49) 3 Fukuoka, Y., see Miwa, T. (49) 65 Fung, M., Loubser, P.G., Mueller, M., Sun, C., Sun, W.N.,

Pinkston, K., Peng, C., Vaughn, W., Fraser Jr., C.D. and Undar, A., Inhibition of complement, neutrophil and platelet activation by a potent anti-factor D antibody during extracor- poreal circulation (49) 68

Fure, H., Bergseth, G., Brekke, O.L. and Mollnes, T.E., Hirudin is an ideal anticoagulant for complement studies in a whole blood inflammatory model (49) 70

Fure, H., see Mollnes, T.E. (49) 62

Gaboriaud, C., Rossi, V., Baby, I., Arlaud, G. and Fontecilla, J.C., X-ray structure of the human Cls catalytic domain: a protease with a CCP module handle (49) 33

Gadjeva, M. and Carroll, M., C4-A like and C4-B like animal models (49) 12

Gadjeva, M., Vorup-Jensen, T., Hansen, A., Thiel, S. and Jense- nius, J.C., Analysis of MASP-2 activation by mutagenesis studies (49) 89

Gadjeva, M.G., see Kojouharova, M.S. (49140 Gal, P., see Zavodszky, P. (49) 89 Galebskaya, L.V., Niemerovsky, V.S., Ryumina, E.V. and Aleshin,

Yu.N., The complement system activity in nonspecific ulcera- tive colitis and after Wobenzyme treatment (49) 23

Gallagher, S., see Dodd, I. (49) 63 Gallardo, E., see Sanchez-Corral, P. (491 45 Galvan, M., see Tacnet, P. (49) 16 Galvan, M.D., see Webster, S.D. (49) 15 Gamba, S., see Caprioli, J. (49) 13 Garcia-Schuler, H., Jurianz, K., Ziegler, S., Rutz, R. and

Kirschfink, M., Cytokines augment complement resistance of human breast carcinoma cells (491 20

Gamier, G., see Sekine, H. (49) 28 Garred, P., Madsen, H.O., Larsen, F. and Koch, C., Inherited

deficiency of mannose-binding lectin is predominantly a type II deficiency state (491 85

Garred, P., see Larsen, F. (49) 84 Garred, P., see Madsen, H.O. (491 87 Gasque, P., see McGreal, E.P. (491 7 Gasque, P., see Dean, Y.D. (49) 41 Gatti, S., see Bergamaschini, L. (49) 23 Gelderman, K.A., Blok, V.T., Fleuren, G.J. and Gorter, A., Bispe-

cific antibody against CD55 and an antigen on cervical carcinoma cells induces C3b deposition and lysis (49) 21

Gerard, C., see Humbles, A.A. (49) 80 Gerard, N.P., see Humbles, A.A. (49) 80 Gewurz, H., see Spear, G.T. (49) 87 Gewurz, H., see Xu, B. (491 88


Ghebrehiwet, B., see Ogden, C.A. (49) 40 Ghiran, I., Barbashov, SF., Klickstein, L.B., Nicholson-Weller,

A. and Israel, B., The binding of mannan binding lectin parallels the expression of complement receptor 1 (CRl, CD351 on erythrocytes and neutrophils (49) 86

Ghiran, I., Klickstein, L.B. and Nicholson-Weller, A., Mannan binding lectin binds complement receptor type 1 and augments IgG-stimulated phagocytosis (49) 3

Giannakis, E., Male, D.A., Ormsby, R.J., Loveland, B.E. and Gordon, D.L., Identification of the streptococcal M-protein binding site on membrane cofactor protein (CD461 (49) 66

Giannakis, E., Male, D.A., Ormsby, R.J., Mold, C., Ranganathan, S. and Gordon, D.L., A common site within factor H SCR 7 responsible for binding heparin, C-reactive protein and streptococcal M protein (49) 57

Giannakis, E., see Sakari Jokiranta, T. (49) 54 Giannakis, E., see Male, D.A. (49) 45 Giannakis, E., see Ormsby, R.J. (49) 45 Giclas, P., see Henry, S.P. (49) 97 Giclas, P.C., see Kang, H.J. (49) 49 Gilbert, D., see Zhakhov, A. (49) 72 Gilkeson, G., see Sekine, H. (49) 28 Gioffre, D., Barilla-La Barca, M.L., Zanichelli, A., Agostoni, A.,

Atkinson, J.P. and Cicardi, M., Autoimmune acquired Cl-INH deficiency and anticardiolipin antibodies (49) 27

Gipson, M., see Guthridge, J. (49) 69 Glabe, C., see Tacnet, P. (49) 16 Gobbo, G., Bergamaschini, L., Macera, F., Di Stefano, R. and

Agostoni, A., ClINH binds to endothelial cells and prevents cell metabolic failure after cold storage (49) 61

Gobbo, G., see Bergamaschini, L. (49) 23 Gonzalez-Rubio, C., see Sanchez-Corral, P. (49) 45 Goodfellow, I., see Spiller, O.B. (49) 67 Goodfellow, I., see Spiller, O.B. (49) 71 Gordon, D.L., see Friese, M.A. (49) 45 Gordon, D.L., see Male, D.A. (49) 45 Gordon, D.L., see Ormsby, R.J. (49) 45 Gordon, D.L., see Sakari Jokiranta, T. (49) 54 Gordon, D.L., see Giannakis, E. (49) 57 Gordon, D.L., see Giannakis, E. (49) 66 Gorringe, A., see Ram, S. (49) 73 Garter, A., see Gelderman, K.A. (49) 21 GGtze, O., see Schieferdecker, H.L. (49) 4 GGtze, O., see Schlaf, G. (49) 48 Graham, R., see Nielsen, C.H. (49) 49 Gregorek, H., see Madalinski, K. (49) 26 Grillo-Lopez, A., see Harjunp’s, A. (49) 20 Grippi, K., see Friedman, H.M. (49) 58 Grove, M., Hoymann, H.G., Meyer-Wiedenbach, I., Zhang, Q.,

Raschke, U., Flemme, N., Meyer zu Vilsendotff, A.M., Klos, A., Kohl, J. and Bautsch, W., A C3a-receptor defective guinea pig strain exhibits decreased bronchial reactivity in an ovalbu- min-induced asthma model (49) 25

Grumach, AS., see Leitao, M.F. (49) 14 Grumach, A.S., see Liberatore Jr., R.D.R. (49) 27 Guerrero, R., see Vidarte, L. (49) 40

Guerrero, R., see Pastor, C. (49) 96 Guillaume, N., see Jean, D. (49) 15 Gulati, S., see Ram, S. (49) 58 Gulati, S., see Ram, S. (49) 73 Gupta-Bansal, R., Parent, J.B., Convery, M. and Brunden, K.R.,

Inhibition of alternative pathway function with anti-properdin MoAbs (49) 68

Gupta-Bansal, R., see Parent, J.B. (49) 68 Guthridge, J., Rakstang, J., Young, K., Hinshelwood, J., Sarrias,

M.R., Moore, W., Perkins, S.J., Overduin, M., Lamb& J.D., Karp, D., Hannan, J. and Holers, V.M., CR2/CD21 SCR1,2 domain ligand binding, physical properties and structural analysis (49) 46

Guthridge, J., Young, K., Gipson, M., Hinshelwood, J., Sarrias, M.R., Lambris, J.D., Perkins, S.J. and Holers, V.M., Novel inhibitory monoclonal antibodies to human CR2/CD21 ligand binding domains (49) 69

Guthridge, J., see Fleming, S.D. (49) 22 Guthridge, J., see Karp, D.R. (49) 46 Guthridge, J.M., see Holers, V.M. (49) 8 Guthridge, J.M., see Fleming, S.D. (49) 37 Guthridge, J.M., see Kraus, D. (49) 64

Hack, C.E., Nijmeijer, R., Niessen, H.W.M., Visser, C.A. and Lagrand, W.K., CRP mediates complement activation in human myocardial infarction (49) 7

Hack, C.E., see Bos, I.G.A.C. (49) 41 Hack, C.E., see Soulika, A.M. (49) 62 Hafer-Macko, C., Dashiell, S.M., Shin, M. and Koski, CL.,

Sublytic terminal complement complexes stimulate cell cycle activation in Schwann cells (49) 16

Hagman, J., see Holers, V.M. (49) 47 Halme, J., see Vogel, H. (49) 63 Halperin, J.A., see Qian, Y.M. (49) 50 Halter, R., see Andr’ii, J. (49) 94 Hamacher, H., see Settmacher, B. (49) 89 Hamasaki, N., see Matsushita, M. (49) 79 Hanna, S.M., Harris, C.L. and Morgan, B.P., Tissue distribution

of mouse CD59 analyzed using a novel rat anti-mouse CD59 monoclonal antibody (49) 92

Hannan, J., see Guthridge, J. (49) 46 Hansch, G.M., see Wagner, C. (49) 47 Hansen, A., see Gadjeva, M. (49) 89 Hansen, F., see Liu, H. (49) 84 Hansen, S., see Liu, H. (49) 84 Hanson, S., see Schwaeble, W.J. (49) 13 Hao, L., see Wang, Y. (49) 19 Harjunpaa, A., Wiklund, T., Junnikkala, S., Janes, R., Collan, J.,

Rosenberg, J., Lee, D., Grillo-Lopez, A. and Meri, S., Direct complement lysis as a major effector mechanism in rituximab (anti-CD20) therapy of B cell lymphomas (49) 20

Harmsen, T., Kuipers, S., Mascini, E.M. and Van Dijk, H., Cross-sectional study on soluble terminal-complement-pathway inhibitor levels in the Dutch population (49) 21

Harmsen, T., see Kuipers, S. (49) 87

Auihor Index of Abstracts 205

Harris, C., see Miwa, T. (49) 25 Harris, CL., Spiller, O.B. and Morgan, B.P., Complement in-

hibitory activity of decay accelerating factor (DAF; CD551 is not species restricted (49) 64

Harris, C.L., see Perez de la Lastra. J.M. (49) 65 Harris, C.L., see Spiller, O.B. (49) 71 Harris, CL., see Lastra, J.M.P. (49) 91 Harris, C.L., see Hanna, SM. (49) 92 Harris, E.N., see Myones, B.L. (49) 97 Harrison, R., Vial, C., Soin, B., Masroor, S., Chavez, G., Bradley,

J., Smith, K., Thiru, S., White, D., Friend, P. and Cozzi, E., TPlO (sCR1) increases protection against complement-mediated damage following xeno-transplantation of hDAF trans- genie pig kidneys into cynomolgus monkeys (49) 63

Harrison, R., see Fecke, W. (49) 91 Hart, M.L., see Spear, G.T. (49) 87 Hattori, T., see Soulika, A.M. (49) 62 Hauhart, R., see Krych-Godberg, M. (49) 62 Haviland, D.L., see Matthews, K.W. (49) 15 Haviland, D.L., see Kildsgaard, J. (49) 80 Haviland, J., see Drouin, S.M. (49) 26 Hawlisch, H., Bautsch, W., Klos, A. and Kohl, J., The N-terminal

part of the 2”d extracellular loop of the C3aR is not involved in agonist binding (49) 44

Hawhsch, H., see Dahlke, M. (49) 12 Heger, M., see Lehmann, T.G. (49) 21 Heinze, G., see Ram, S. (49) 73 Hellwage, J., Jarva, H., Zipfel, P.F. and Meri, S., Factor H-related

proteins interact with C-reactive protein (49) 70 Hellwage, J., see Sakari Jokiranta, T. (49) 44 Hellwage, J., see Friese, M.A. (49) 45 Hellwage, J., see Sakari Jokiranta, T. (49) 54 Hellwage, J., see Meri, T. (49) 57 Hellwage, J., see Jarva, H. (49) 69 Henry, S.P., Jagels, M., Hugli, T. and Giclas, P., Species and

pathway-specific activation of complement by a phosphoro- thioate oligonucleotide (49) 97

Henson, P., see Botto, M. (49) 36 Henson, P., see Ogden. C.A. (49) 40 Henson, SE., see Karp, D.R. (49) 46 Herbert, A.P. and Barlow, P.N., Studies to determine the struc-

tural effect of the N-glycan on CCP module 2 of membrane cofactor protein (49) 65

Heske, C., see Andrl, J. (49) 94 Hess, M.W.. Schwendinger, M.G., Eskelinen, E.L., Pfaller, K.,

Pavelka, M., Dierich, M.P. and Prodinger, W.M., Tracing uptake of CSdg-conjugated antigen into B-cells via complement receptor type 2 (49) 49

Hidaka, M., see Endo, M. (49) 86 Hieble, J.P., see Ames, R.S. (49) 53 Hietala, A., see Persson, L. (49) 20 Hila, S., Niculescu. F. and Koski, CL., Sublytic terminal comple-

ment complexes (TCC) rescued Schwann cells (SchC) from apoptosis via PI-3 kinase-Akt/PKB pathway (49) 16

Hinchliffe, S.J., see Perez de la Lastra, J,M. (49) 65 Hino, J., see Kinoshita, T. (49) 92

Hinshelwood, J. and Perkins, S.J., Conformational changes during the assembly of factor B from its domains by ‘H NMR: the regulation of factor B activity (49) 42

Hinshelwood, J. and Perkins, S.J., Metal-dependent conformational changes in the vWF-A domain from factor B: a study by CD, FT-IR and ‘H NMR spectroscopy (49) 42

Hinshelwood, J., Spencer, DIR., Edwards, Y.J.K. and Perkins, S.J., Identification of the C3b binding site in the vWF-A domain of factor B by SELDI mass spectrometry and homol- ogy modelling (49) 32

Hinshelwood, J., see Guthridge, J. (49) 46 Hinshelwood, J., see Guthridge, J. (49) 69 Hitsumoto, Y., Matsuda, T. and Okada, M., Inhibition of human

C4 step by mouse fibronectin (49) 70 Hitsumoto, Y., see Okada, M. (49) 70 Hochman, I., see Fishelson, Z. (49) 97 Hoedemaeker, P.J., see Bos, I.G.A.C. (49) 41 Ho&, V.M., MO, L., Guthridge, J.M., Mohna, H. and Salmon,

J.E., Crry-Ig, an inhibitor of C3 activation, blocks anti-phos- pholipid AB (aPL) induced fetal loss (49) 8

Holers, V.M., Ulgiati, D., Hagman, J. and Makar, K.W., Identifi- cation of a specific site within the human CR2/CD21 transcriptional silencer that controls lineage-specific repression: Interaction with a multi-protein complex containing CBFl, a target of the Notch signaling pathway (49) 47

Holers, V.M., see Ulgiati, D. (49) 14 Holers, V.M., see Fleming, S.D. (49) 22 Holers, V.M., see Fleming, S.D. (49) 37 Holers, V.M., see Boackle, S.A. (49) 29 Holers, V.M., see Guthridge, J. (49) 46 Holers, V.M., see Karp, D.R. (49) 46 Holers, V.M., see Marchbank, K.J. (49) 47 Holers, V.M., see Kang, H.J. (49) 49 Holers, V.M., see Kraus, D. (49) 64 Holers, V.M., see Kang, B.H.J. (49) 68 Holers, V.M., see Guthridge, J. (49) 69 Hollmann, T.J., see Kildsgaard, J. (49) SO Holmstriim, E., see Selander, B. (49) 74 Holt, D.S., Botto, M., Bygrave, A.E., Rushmere, N.K., Walport,

M.J. and Morgan, B.P., Knocking out mouse CD59 using a PCR derived gene targeting vector (49) 67

Holt, D.S., see Perez de la Lastra, J.M. (49) 65 Hourcade, D., see Moulds, J.M. (49) i3 Hourcade, D., see Kuttner-Kondo, L. (49) 64 Hourcade, D., see Mitchell, L. (49) 64 Hourcade, D.E., see Kang, B.H.J. (49) 68 Hoymann, H.G., see Grove, M. (49) 25 Hsiao, K., see Yu, J.X. (49) 7 Huber-Lang, M., Younkin, E., McGuire, S.R., Lu, K., Sarma, V.

and Ward, P.A., C5a generation by alveolar macrophages (49) 47

Huber-Lang, M., see Ward, P.A. (49) 23 Hugli, T., see Henry, S.P. (49) 97 Humbles, A.A., Lu, B., Gerard, N.P. and Gerard, C., C3aR: a

central mediator of allergic asthma (49) 80 Hunfeld, K.-P., see Kraiczy, P. (49) 75


moue, N., see Kinoshita, T. (49) 92 Ippolito, G.C., see Xu, Y. (49) 80 Irigoin, F., Ferreira, F., Laich, A., Fernandez, C., Ferreira, A.,

Sim, R.B. and Diaz, A., Characterization of an inhibitor of complement activation from the parasite Echinococcus granu- losus (49) 75

Isaac, L., see Liberatore Jr., R.D.R. (49) 27 Ischenko, A., see Zhakhov, A. (49) 72 Isenman, D.E., see Van den Elsen, J.M.H. (49) 32 Isenman, D.E., see Clemenza, L. (49) 33 Isenman, D.E., see Pan, Q. (49) 54 Ishii, N., see Takahashi, M. (49) 3 Israel, B., see Ghiran, I. (49) 86

Jaatinen, T., Poutanen, K., Kanerva, J., Saarinen-Pihkala, U. and Lokki, M.-L., Extraordinary transcript of human factor B (Bf) generated by intron retention (49) 43

Jack, D.L., Jarvis, G.A., Booth, C.L., Li, J., Klein, N.J. and Turner, M.W., Meningococcal lipopolysaccharide sialylation alters the bactericidal activity of human mannose-binding lectin (49) 88

Jack, D.L., Vogel, U., Tenner, A.J., Frosch, M., Turner, M.W. and Klein, N.J., Regulation of the inflammatory response to Neisseria meningitidis B 1940 by mannose-binding lectin (49) 88

Jackson, J., see Sanderson, S. (49) 96 Jagels, M., see Henry, S.P. (49) 97 Janes, R., see Harjunpll, A. (49) 20 Jarva, H., Hellwage, J. and Meri, S., Regulation of the alternative

pathway on injured cells by Factor H, FHL-1 and C-reactive protein (49) 69

Jarva, H., see Hellwage, J. (49) 70 Jarvis, G.A., see Jack, D.L. (49) 88 Jaworska, H., see Madalinski, K. (49) 26 Jean, D., Guillaume, N. and Frade, R., Characterization of the

promoter of human procathepsin-L gene, a proteinase which cleaves human C3, the third component of complement and confers high tumorigenic and metastatic properties to human melanoma cells (49) 15

Jelezarova, E. and Lutz, H.U., Efficient assembly of a C3 convertase on C3b,-IgG complexes (49) 95

Jelezarova, E., see Lutz, H.U. (49) 67 Jensen, L., see Petersen, S.V. (49) 83 Jensen, L., see Liu, H. (49) 84 Jensen, T.G., see Vorup-Jensen, T. (49) 86 Jensen, U.B., see Vorup-Jensen, T. (49) 86 Jensenius, J.C., Matsushita, M., Thiel, S. and Fujita, T., Two

molecular forms of MBL/MASP complexes differing in size, composition and biological activity are present in human plasma (49) 33

Jensenius, J.C., see Dahl, M.R. (49) 79 Jensenius, J.C., see Petersen, S.V. (49) 83 Jensenius, J.C., see Liu, H. (49) 84 Jensenius, J.C., see Vorup-Jensen, T. (49) 86 Jensenius, J.C., see Thielens, N. (49) 87 Jensenius, J.C., see Gadjeva, M. (49) 89 Jensenius, J.Chr., see Thiel, S. (49) 85

Ji, X., Namikawa-Yamada, C., Nakanishi, M., Sasaki, M. and Nonaka, M., Molecular cloning of complement factor B from a solitary ascidian: unique combination of domains implicating ancient exon shufflings (49) 43

Ji, X.-D., see Chronopoulou, E. (49) 89 Jia, H.P., see Drouin, S.M. (49) 26 Jiang, H. and Frank, M.M., An IgG Fc fragment peptide blocks

interaction of IgG with Clq (49) 69 Jiang, H., see Wagner, E. (49) 61 Jiang, M., see Friedman, H.M. (49) 58 Johnson, R.S., see Xu, Y. (49) 80 Jokiranta, T.S., see Friese, M.A. (49) 45 Jones, J.C., see Karp, D.R. (49) 46 Jones, K.N., see Yung Yu, C. (49) 32 Jonsson, A.-B., see Kallstrom, H. (49) 75 Jordan, J.E., Morrissey, M. and Stahl, G.L., Anti-complement

treatment protects hypoxic-reoxygenated HUVECS from apoptosis (49) 24

Jams, A., see Meyer zu Vilsendorf, A. (49) 22 Jozsi, M., see Erdei, A. (49) 84 Jungermann, K., see Schieferdecker, H.L. (49) 4 Jungermann, K., see Schlaf, G. (49) 48 Junnikkala, S., see HarjunpZi, A. (49) 20 Jurianz, K., see Garcia-S&tiler, H. (49) 20 Justus, D.E., see Kotwal, G.J. (49) 76

Kacani, L., Prodinger, W.M., Sprinzl, G.M., Schwendinger, M.G., Stoiber, H., Steindl, F. and Dierich, M.P., Detachment of HIV-l from follicular dendritic cells by blocking the C3d-CR2 interaction (49) 72

Kahn, D., see Loveland, B.E. (49) 66 Kallstrom, H., Blackmer, D.J., Liszewski, M.K., Atkinson, J.P.

and Jonsson, A.-B., Attachment of Neisseria gonorrhoeae to the cellular pilus receptor CD46: identification of domains important for bacterial adherence (49) 75

Kane, T.M., see Regal, J.F. (49) 26 Kanerva, J., see Jaatinen, T. (49) 43 Kang, B.H.J., Mitchell, L.M., Hourcade, D.E. and Holers, V.M.,

A novel anti-human factor B monoclonal antibody inhibits factor D-mediated association and cleavage of factor B (49) 68

Kang, H.J., Bao, L., Ma, Y., Quigg, R., Giclas, P.C. and Holers, V.M., Increased serum C3 in soluble Crry transgenic mice: evidence of potential counter-regulation in the setting of chronic over-expression of a C3 convertase inhibitor that partially abrogates its effects (49) 49

Kangawa, K., see Kinoshita, T. (49) 92 Karp, D., see Guthridge, J. (49) 46 Karp, D.R., Henson, S.E., Jones, J.C., Guthridge, J. and Holers,

V.M., Generation of novel C3dg tetramers for the analysis of CD21 binding and function (49) 46

Kassambara, L., see Moulds, J.M. (49) 73 Kato, Y., see Nakao, M. (49) 11 Kato, Y., see Nakao, M. (49) 12 Katsuragi, T., see Abe, M. (49) 26 Katyal, M., see Ayub, S. (49) 48 Kaveri, S., see Leslie, R.G.Q. (49) 24 Kaveri, S., see Nielsen, C.H. (49) 49


Kawasaki, N., see Kawasaki, T. (49) 85 Kawasaki, T., Ma, Y., Uemura, K. and Kawasaki, N., Mannan-bi-

nding protein (MBP)-dependent cell-mediated cytotoxicity (MDCC) (491 85

Kawasaki, T., see Vorup-Jensen, T. (49) 86 Kayhty, H., see Selander, B. (49) 74 Kazatchkine, M.D., see Fremeaux-Bacchi, V. (49) 14 Kazatchkine, M.D., see Leslie, R.G.Q. (491 24 Kazatchkine, M.D., see Nielsen, C.H. (49) 49 Kemper, C., Leung, M., Liszewski, M.K. and Atkinson, J.P.,

Characterization of MCP (CD461 transgenic mice (491 66 Kemper, C., Riley, R.C., Leung, M. and Atkinson, J.P., Character-

ization of human membrane cofactor protein (MCP, CD461 on spermatozoa (49166

Kenjo, A., Takahashi, M., Matsushita, M., Endo, Y. and Fujita, T., A ticolin-like lectin in the plasma of the solitary ascidian, Halocynthia roretzi (49) 84

Khan, M.M., see Soulika, A.M. (49) 62 Kildsgaard, J., Hollmann, T.J., Matthews, K.W., Drouin, SM.,

Haviland, D.L. and Wetsel, R.A., Contraposition of endotoxin-induced shock in C3a receptor- and C3-deficient mice (491 80

Kildsgaard, J., see Drouin, SM. (49) 26 Kildsgaard, J., see Matthews, K.W. (49) 15 Kim, K.-C., Vreeke, T.M. and Parker, C.J., Effects of mutant

PIG-A on gene expression (49) 93 Kinoshita, T., Watanabe, R., Murakami, Y., Inoue, N., Maeda, Y.,

Hino, J. and Kangawa, K., PIG-P, the fourth protein associated with PIG-A that is responsible for paroxysmal nocturnal hemoglobinuria (49) 92

Kirschfink, M., see Leitao, M.F. (49) 14 Kirschfink, M., see Garcia-Schller, H. (49) 20 Kirschfink, M., see Lehmann, T.G. (49) 21 Kirschfink, M., see Liberatore Jr., R.D.R. (49) 27 Kirschfink, M., see Kraiczy, P. (49) 57 Kirschfink, M., see Vogel, H. (491 63 Kishore, U., see Reid, K.B.M. (49) 17 Kishore, U., see Kojouharova, M.S. (49) 40 Kitamura, H., see Kitano, E. (49) 43 Kitano, E. and Kitamura, H., Synthesis of factor D by normal

human hepatocytes (49) 43 Klar, E., see Lehmann, T.G. (49) 21 Klein, N.J., see Jack, D.L. (49) 88 Klein, P., see Szebeni, J. (49) 71 Klickstein, L.B., see Ghiran, 1. (49) 3 Klickstein, L.B., see Ghiran, I. (491 86 Klickstein, L.B., see Tyagi, S.R. (49) 4 Klickstein, L.B., see Vincent, J.A. (49) 90 Klos, A., see Dahlke, M. (49) 12 Klos, A., see Grove, M. (49) 25 Klos, A., see Hawlisch, H. (491 44 Klos, A., see Ames, R.S. (49) 53 Klos, A., see Settmacher, B. (491 89 Knipe, D.M., see Verschoor, A. (49) 72 Koch, C., see Larsen, F. (49) 84 Koch, C., see Garred, P. (49) 85 Koch, C., see Thiel, S. (49) 85

Koenig, K., see Szebeni, J. (49) 71 Kohl, J., see Dahlke, M. (49) 12 Kohl, J., see Meyer zu Vilsendorf, A. (49) 22 Kohl, J., see Grove, M. (49) 25 Kohl, J., see Hawlisch, H. (49) 44 Kohl, J., see Mollnes, T.E. (49) 62 Kohl, J., see Settmacher, B. (49) 89 Kohl, J., see Link, C. (49) 90 Kojima, M. and Sim, R.B., Study of MBL-MASPs interaction

with Cl-inhibitor and (Y ,-macroglobulin (49) 88 Kojouharova, MS., Tzacheva, LG., Gadjeva, M.G., Tchorbad-

jieva, M.I., Kishore, U. and Reid, K.B.M., Localisation of ligand-binding sites on Clq globular regions using single-chain antibodies (49) 40

Kolb, W.P., see Ember, J.A. (49) 91 Koleva, M., see Schieferdecker, H.L. (49) 4 Kondor, N., see Miwa, T. (49) 65 Koppenheffer, T.L. and Parker, K.P., Complement-dependent and

-independent activities of cobra venom factor-treated chicken serum (49) 94

Koski, CL., see Hafer-Macko, C. (49) 16 Koski, C.L., see Hila, S. (49) 16 Kotwal, G.J., Smith, S., Al Mohanna, F., Parhar, R., Srisatjaluk,

R., Justus, D.E., Mullins, N., Parkinson, J. and Barlow, P., Heparin binding activity (due to putative K/R-X-R/K sites) of vaccinia virus complement control protein confers numer- ous functions with tremendous therapeutic potential and implications in viral evasion (49) 76

Kraiczy, P., Hunfeld, K.-P., Wirzner, R., Acker, G. and Brade, V., Studies on the borreliacidal activity of early Lyme disease sera against complement-resistant Borrelia afzelii FEMl wild- type and an OspC-lacking FEMl variant (49) 75

Kraiczy, P., Skerka, C., Kirschfink, M., Brade, V. and Zipfel, P.F., Serum resistance of Borrelia burgdorferi correlates with binding of essential immune regulators of the factor H-protein family (49) 57

Kraus, D., Guthridge, J.M., Marsh Jr., H.C. and Holers, V.M., A direct comparison of complement inhibitory capacities of the GPI- and transmembrane forms of mouse DAF to mouse Crry and human rsCR1 (49) 64

Kristan, J., see Wang, Y. (49) 19 Krych-Godberg, M., Hauhart, R., Blackmer, D. and Atkinson,

J.P., Structural requirements for decay accelerating activity (DAA) in complement receptor 1 (CRl; CD35) (491 62

Krych-Goldberg, M., see Mallin, R. (49) 46 Krych-Goldberg, M., see Smith, B.O. (49) 46 Krych, M., see Moulds, J.M. (49) 73 Kuipers, S., Harmsen, T., Mascini, E., Takahashi, K. and Van Dijk.

H., Mannose-binding lectin in the Netherlands: prevalence of normal and aberrant levels in a healthy population (491 87

Kuipers, S., see Harmsen, T. (49) 21 Kunze, B., see Bammert, H. (49) 12 Kuraya, M., Endo, Y., Matsushita, M. and Fujita, T., P35-related

gene expression in neutrophils as well as monocytes (49) 11 Kuttner-Kondo, L., Mitchell, L., Hourcade, D. and Medof, M.E.,

Characterization of the active site in decay-accelerating factor (DAF) (49164

208 Author Index ofAbstracts

Kuttner-Kondo, L., see Mitchell, L. (49) 64 Kyriakou, P., see Loveland, B.E. (49) 66

Lachmann, P.J., see Smith, G.P. (49) 53 Lachmann, P.J., see Margos, G. (49) 73 Lachmann, P.J., see Fernie-King, B.A. (49) 74 Lacouture, M.E., see Vincent, J.A. (491 90 Lagrand, W.K., see Hack, C.E. (49) 7 Laich, A. and Sim, R.B., Investigation of C4bC2 complex forma-

tion by surface plasmon resonance (49) 42 Laich, A., see Irigoin, F. (49) 75 Lambris, J.A., see Song, W.C. (49) 24 Lambris, J.D., see Mastellos, D. (491 8 Lambris, J.D., see Franchini, S. (49) 13 Lambris, J.D., see Zarkadis, LK. (49) 13 Lambris, J.D., see Moore, W.T. (49) 43 Lambris, J.D., see Guthridge, J. (49) 46 Lambris, J.D., see Sahu, A. (49) 53 Lambris, J.D., see Friedman, H.M. (49) 58 Lambris, J.D., see Soulika, A.M. (49) 62 Lambris, J.D., see Guthridge, J. (49) 69 Lamb& J.L., see Mollnes, T.E. (49) 62 Lanteri, M., see Loveland, B.E. (491 66 Lappeglrd, K.T., see Mollnes, T.E. (49) 62 Larsen, C.P., see Regal, J.F. (49) 26 Larsen, F., Madsen, H.O., Koch, C. and Garred, P., Construction

and expression of variant forms of human mannose-binding lectin (49) 84

Larsen, F., see Garred, P. (49) 85 Lassiter, H., Feldhoff, P., Dabhia, N., Parker, J. and Feldhoff, R.,

Cobra venom factor (CVF) reduces hypoxic-ischemic (HI) cerebral edema in neonatal rats (49) 22

Lassiter, H., see Andrews, E. (491 19 Lassiter, H., see Feldhoff, P. (49) 44 Lastra, J.M.P., Harris, CL. and Morgan, B.P., Distribution of

decay accelerating factor (DAF/CDSSl on pig cells and tissues (491 91

Lee, D., see Harjunp%i, A. (49) 20 Lee, D., see Ames, R.S. (491 53 Lefer, A.M., see Song, W.C. (491 24 Lehmann, T.G., Mlnch, S., Heger, M., Klar, E. and Kirschfink,

M., Liver ischemia/reperfusion injury: a comparison of the protective effect of the complement inhibitors rsCR1 and Cl inhibitor (49) 21

Leitao, M.F., Condino-Neto, A., Grumach, A.S. and Kirschfink, M., Factor I deficiency: evaluation in three generations of a Brazilian family (49) 14

Lenkoski, C.S., see Wang, Y. (49) 19 Le Romancer, M., Barel, M. and Frade, R., Use of yeast two-hy-

brid screening to identity intracellular components which interact directly with the C3d/Epstein_Barr virus receptor (gp140, CR2, CD211 in human B lymphocytes (49) 50

Leslie, Q., see Nielsen, C.H. (49) 49 Leslie, R.G.Q., Kaveri, S., Kazatchkine, M.D., Fisher, E.M. and

Nielsen, C.H., Opsonised immune complexes containing au- toantigen and natural autoantibodies rescue peripheral blood B cells from apoptosis (491 24

Leung, M., see Liszewski, M.K. (49) 54 Leung, M., see Kemper, C. (49) 66 Li, J., see Jack, D.L. (491 88 Li, W.X., see Miwa, T. (49) 65 Liang, G., see Birmingham, D.J. (49) 29 Liang, H. and Aheam, J.M., A hemagglutinin-C3d2 fusion protein

protects mice from lethal infection with influenza virus (49) 58

Liberatore Jr., R.D.R., Barbosa, S.F.C., Alkimin, M.G.A., Belli- nati-Pires, R., Florido, M.P.C., Isaac, L., Kirschfink, M. and Grumach, A.S., Analysis of immunoglobulins, complement and phagocyte in children and adolescents with diabetes melli- tus type 1 (49) 27

Lindahl, G., see Berggkd, K. (49) 75 Lindahl, G., see Blom, A.M. (49) 74 Link, C. and Kohl, J., Macrophages and xenoreactive antibodies

mediate delayed xenograft rejection in the discordant guinea pig to rat species combination (49) 90

Link, C., see Dahlke, M. (491 12 Link, C., see Meyer zu Vilsendotf, A. (49) 22 Lint, T.F., see Xu, B. (49) 88 Linton, S.M., see Dodd, I. (49) 63 Liszewski, M.K., Leung, M., Cui, W., Bala Subramanian, V.,

Manchester, M., Parkinson, J., Barlow, P. and Atkinson, J., Membrane cofactor protein (MCP; CD46): dissecting sites important for complement regulatory activity (49) 54

Liszewski, M.K., see Kemper, C. (49) 66 Liszewski, M.K., see Kallstrom, H. (49) 75 Liu, H., Jensen, L., Hansen, S., Petersen, S.V., Takahashi, K.,

Ezekowitz, A., Hansen, F., Jensenius, J.C. and Thiel, S., Analysis of mouse mannan-binding lectin A and C (49) 84

Liu, X., see Myones, B.L. (49) 97 Logar, C.M., see Birmingham, D.J. (491 11 Lokki, M.-L., see Jaatinen, T. (49) 43 Long, J., see Fecke, W. (49) 91 Loos, M., see Schwaeble, W.J. (49) 15 Loos, M., see Petty, F. (491 79 L6pez-Trascasa, M., see Sanchez-Corral, P. (49) 45 Lorincz, Z., see Zavodszky, P. (49) 89 Loubser, P.G., see Fung, M. (49) 68 Loveland, B.E., Milland, J., Thorley, B., Christiansen, D., Kyri-

akou, P., Lanteri, M., French, A., Williams, L., Baker, L., Brandon, M.R., Bellomo, R., Baldwin, I., Kahn, D. and McKenzie, I.F.C., Characterisation of a transgenic pig line expressing high levels of CD46 (49) 66

Loveland, B.E., see Giant&is, E. (49) 66 Lovik, G., Vaage, J.T., Ryan, J.C., Szpirer, C., Dissen, E. and

Rolstad, B., Cloning and characterization of rat ClqRp (49) 41 Lu, B., see Humbles, A.A. (49) 80 Lu, K., see Huber-Lang, M. (49) 47 Luan, F.J., see Ember, J.A. (49) 91 Lubinski, J., see Friedman, H.M. (49) 58 Lucas, A.H., see Test, S.T. (491 44 Lucisano-Valim, Y.M., see Marzocchi-Machado, C.M. (49) 90 Lutz, H.U., Stammler, P. and Jelezarova, E., Natural inhibitors of

complement amplification anti-C3 antibodies from IVIG stimulate inactivation of C3bncontaining complexes (49) 67

Lutz, H.U., see Jelezarova, E. (49) 95


Ma, M., see Xu, Y. (49) 80 Ma, Y., see Kang, H.J. (49) 49 Ma, Y., see Kawasaki, T. (49) 85 Macera, F., see Gobbo, G. (49) 61 Mackinnon, F.G., see Ram, S. (49) 73 Madalinski, K., Jaworska, H. and Gregorek, H., Should we use

probiotics as supportive treatment for hereditary angioedema? (49) 26

Madsen, H.O., Svejgaard, A., Ryder, L.P. and Garred, P., The evolution of human mannose-binding lectin genes mbll and mb12 (49) 87

Madsen, H.O., see Larsen, F. (49) 84 Madsen, H.O., see Garred, P. (49) 85 Maeda, Y., see Kinoshita, T. (49) 92 Magnoli, F.C., see Van den Berg, C.W. (49) 95 Makar, K.W., see Holers, V.M. (49) 47 Maldonado, M., see Miwa, T. (49) 2.5 Male, D.A., Ormsby, R.J., Ranganathan, S., Giannakis, E. and

Gordon, D.L., Sequence analysis of 222 kb of human genomic DNA containing the entire fH, MR-1 and MR-3 genes (49) 45

Male, D.A., see Ormsby, R.J. (49) 45 Male, D.A., see Sakari Jokiranta, T. (49) 54 Male, D.A., see Giannakis, E. (49) 57 Male, D.A., see Giannakis, E. (49) 66 Mallin, R., Smith, B.O., Uhrin, D., Krych-Goldberg, M., Wang,

X., Atkinson, J.P. and Barlow, P.N., Towards a 3D structure of functional site 2 of CR1 - NMR studies of complement control protein (CCP) modules 16 and 17 (49) 46

Manchester, M., see Liszewski, M.K. (49) 54 Mandik-Nayak, L., see Paul, E. (49) 42 Mao, D., see Molina, H. (49) 80 Marchbank, K.J., Watson, C.C., Ritsema, D.F. and Holers, V.M.,

Expression of human complement receptor 2 (CR2, CD21) in CR2-‘- mice restores humoral immune function (49) 47

Marche, P.N., see Villiers, CL. (49) 48 Margos, G., Butcher, G.A., Davies, A., Sinden, R.E. and Lach-

mann, P.J., Interaction between complement and the malaria parasite in the mosquito vector (49) 73

Marsh Jr., H.C., see Kraus, D. (49) 64 Martin, A., see Van den Elsen, J.M.H. (49) 32 Martin, B., see Campos-Totres, A. (49) 48 Marzocchi-Machado, C.M., Russo, E.S.M., Alves, C.M.O.S., Az-

zolini, A.E.C.S., Polizello, A.C.M. and Lucisano-Valim, Y.M., Effect of m-prednisolone upon the complement and Fey receptors ability of mediating oxidative burst of neutrophils (49) 90

Mas, S., see Vidarte, L. (49) 40 Mas, S., see Pastor, C. (49) 96 Mascini, E., see Kuipers, S. (49) 87 Mascini, E.M., see Harmsen, T. (49) 21 Masroor, S., see Harrison, R. (49) 63 Mastellos, D., Papadimitriou, J.C., Franchini, S., Tsonis, P.A. and

Lambris, J.D., A role of complement component C5 in liver regeneration (49) 8

Matis, L.A., see Wang, Y. (49) 19 Matre, R., see Bjorge, L. (49) 21 Matsuda, T., see Hitsumoto, Y. (49) 70

Matsuo, S., see Mizuno, M. (49) 63 Matsushita, M., Endo, Y., Hamasaki, N. and Fujita, T., Ficolins

activate the lectin complement pathway (49) 79 Matsushita, M., see Takahashi, M. (49) 3 Matsushita, M., see Kuraya, M. (49) 11 Matsushita, M., see Jensenius, J.C. (49) 33 Matsushita, M., see Kenjo, A. (49) 84 Matsushita, M., see Endo, M. (49) 86 Matthews, K.W., Kildsgaard, J., Haviland, D.L. and Wetsel, R.A.,

Characterization of the mouse carboxypeptidase N small active subunit gene structure (49) 15

Matthews, K.W., see Kildsgaard, J. (49) 80 McCafferty, G., see Ames, R.S. (49) 53 McCray, P.B., see Drouin, S.M. (49) 26 M&real, E.P., Dean, Y.D., Van den Berg, C., Morgan, B.P. and

Gasque, P., Role of the phagocytic C 1 qR (C 1qRp) in the CNS: identification of the signalling events following ClqRp crosslinking (49) 7

McGreal, E.P., see Dean, Y.D. (49) 41 McGuire, S.R., see Huber-Lang, M. (49) 47 McKenzie, I.F.C., see Loveland, B.E. (49) 66 McQuillen, D.P., see Ram, S. (49) 58 Mead, R.J., Singhrao, S., Neal, J.W. and Morgan, B.P., The

Membrane Attack Complex (MAC) of complement causes severe demyelination in ciuo. Evidence from C6 deficient rats (49) 7

Medof, M.E., see Brodbeck, W.G. (49) 65 Medof, M.E., see Kuttner-Kondo, L. (49) 64 Medof, M.E., see Mitchell, L. (49) 64 Meiling, K.M., see Wehrhahn, D. (49) 94 Meri, S., see Harjunp’ria, A. (49) 20 Meri, S., see Bjorge, L. (49) 21 Meri, S., see Sakari Jokiranta, T. (49) 44 Meri, S., see Sakari Jokiranta, T. (49) 54 Meri, S., see Friese, M.A. (49) 45 Meri, S., see Meri, T. (49) 57 Meri, S., see Jarva, H. (49) 69 Meri, S., see Hellwage, J. (49) 70 Meri, T., Sakari Jokiranta, T., Hellwage, J., Bialonski, A., Meri,

S. and Zipfel, P.F., Onchocerca voluulus -microfilariae avoid complement attact by direct binding of Factor H (49) 57

Mesellis, M., see Amodeo, G. (49) 24 Meyer-Wiedenbach, I., see Grove. M. (49) 25 Meyer zu Vilsendorf, A., Link, C., Jijms, A. and Kohl, J., Prosta-

cyclin analog epoprostenol and cobra venom factor prevents reperfusion injury and hyperacute rejection in discordant liver transplantation (49) 22

Meyer zu Vilsendorff, A.M., see Grove. M. (49) 25 Milland, J., see Loveland, B.E. (49) 66 Miller, L., see Moulds, J.M. (49) 73 Mitchell, D.A., Cook, H.T., Botto, M. and Walport, M.J., Clq

deficiency and autoimmunity: the effects of genetic back- ground on disease expression (49) 18

Mitchell, L., Kuttner-Kondo, L., Medof, M.E. and Hourcade, D., Identification of a factor B site involved in the dissociation of the AP C3 convertase by decay accelerating factor (49) 64

Mitchell, L., see Kuttner-Kondo, L. (49) 64


Mitchell, L.M., see Kang, B.H.J. (49) 68 Mitsuyoshi, J., see Test, ST. (49) 44 Miura, S., see Takahashi, M. (49) 3 Miwa, T., Fukuoka, Y., Okada, N., Kondor, N., Li, W.X. and

Okada, H., Molecular analysis of two closely related mouse decay-accelerating factor (CD55, DAF): genes identification in both of sequences encoding glycosylphosphatidylinositol- anchored and transmembrane forms of DAF (49) 65

Miwa, T., Maldonado, M., Sun, X., Ohta, R., Okada, H., Harris, C., Morgan, B.P., Eisenberg, R.A. and Song, W.C., Tissue expression pattern of the mouse GPI-DAF and its potential role in a murine model of autoimmune disease (49) 25

Miwa, T., Okada, N. and Okada, H., Alternative exon usage in the 3’region of a single gene generates glycosylphosphatidylinositol-anchored and transmembrane forms of rat decay-accelerating factor (49) 92

Miwa, T., see Song, W.C. (49) 24 Miwa, T., see Qian, Y.M. (49) 50 Miyazawa, S. and Nonaka, M., Cloning and characterization of

ascidian integrin subunits that function as a complement receptor type 3 (49) 3

Mizuno, M., Nishikawa, K., Okada, N., Okada, H. and Matsuo, S., Soluble complement receptor (sCR1) 1 rescues rats from lethal shock induced by priming of sublethal dose of lipopolysaccharide (LPS) and anti-&y antibodies (49) 63

MO, L., see Holers, V.M. (49) 8 Mohacsi, P., see Rieben, R. (49) 71 Mohacsi, P., see Walpen, A. (49) 91 Mold, C. and Morris, CA., Activation of complement by apop-

totic endothelial cells following hypoxia/reoxygenation (49) 25

Mold, C., see Giannakis, E. (49) 57 Mold, C., see Brodbeck, W.G. (49) 6.5 Molina, H., Xu, C. and Mao, D., Regulation of the alternative

pathway of complement activation is critical for the maintenance of fetomaternal tolerance (49) 80

Molina, H., see Holers, V.M. (49) 8 Mollnes, T.E., Brekke, O.L., Kohl, J., Bergseth, G., Christiansen,

D., Fure, H., Lappegtid, K.T., Videm, V., Sahu, A. and Lambris, J.L., Inhibition of endotoxin-induced oxidative burst by the C3 binding peptide Compstatin in a novel whole blood model of inflammation (49) 62

Mollnes, T.E., see Fure, H. (49) 70 Monks, B.G., see Ram, S. (49) 58 Montalto, M., see Collard, CD. (49) 85 Montalto, M.C., Wada, K., Whoolery, K.L. and Stahl, G.L.,

Mechanisms of anti-C5 mediated protection following gas- trointestinal ischemia-reperfusion: analysis of intracellular adhesion molecule-l (ICAM-l), tumor necrosis factor-o (TNF), interleukin (IL) -1 o and nitric oxide synthase (NOS) (49) 19

Moore, W., see Guthridge, J. (49) 46 Moore, W.T. and Lamb& J.D., Proteomic analysis of C3 and its

fragments (49) 43 Moore, W.T., see Sahu, A. (49) 53 Morgan, B.P., see McGreal, E.P. (49) 7 Morgan, B.P., see Mead, R.J. (49) 7 Morgan, B.P., see Miwa, T. (49) 25

Morgan, B.P., see Dean, Y.D. (49) 41 Morgan, B.P., see Smith, G.P. (49) 53 Morgan, B.P., see Dodd, I. (49) 63 Morgan, B.P., see Harris, CL. (49) 64 Morgan, B.P., see Perez de la Lastra, J.M. (49) 65 Morgan, B.P., see Holt, D.S. (49) 67 Morgan, B.P., see Spiller, O.B. (49) 67 Morgan, B.P., see Spiller, O.B. (49) 71 Morgan, B.P., see Lastra, J.M.P. (49) 91 Morgan, B.P., see Hanna, S.M. (49) 92 Morgan, E., see Chronopoulou, E. (49) 89 Morgan, E., see Ember, J.A. (49) 91 Morikis, D., see Sahu, A. (49) 53 Morris, C.A., see Mold, C. (49) 25 Morrissey, M., see Jordan, J.E. (49) 24 Moulds, J.M., Roberts, S., Tew, M., Reveille, J. and Alarcon, G.,

Erythrocyte CR1 levels do not correlate with disease activity in Hispanic SLE patients (49) 29

Moulds, J.M., Zimmerman, P., Birmingham, D., Doumbo, O., Kassambara, L., Sagara, I., Atkinson, J.P., Krych, M., Hour- cade, D. and Miller, L., Molecular identification of the CRl- related blood group antigens implicated in malarial infection (49) 73

Moulds, J.M., see Rupert, K.L. (49) 29 Mueller, M., see Fung, M. (49) 68 Muggia, F.M., see Szebeni, J. (49) 71 Mulligan, A., see Zahedi, K. (49) 41 Mullins, N., see Kotwal, G.J. (49) 76 Munch, S., see Lehmann, T.G. (49) 21 Murakami, Y., see Kinoshita, T. (49) 92 Mutsuro, J., see Nakao, M. (49) 12 Myones, B.L., Espinola, R., Liu, X., Antonov, I.V., Harris, E.N.

and Pierangeli, S.S., Complexes of factor H and phospholipids induce pathogenic antiphospholipid antibodies in a murine model (49) 97

Nakanishi, M., see Ji, X. (49) 43 Nakao, M., Mutsuro, J., Tanaka, N., Totsuka, S., Kato, Y., Fujiki,

K. and Yano, T., Two divergent C4 isotypes of the common carp (49) 12

Nakao, M., Osaka, K., Kato, Y. and Yano, T., Molecular cloning of Clr/Cls-like serine protease from the common carp (49) 11

Namikawa-Yamada, C., see Ji, X. (49) 43 Nauta, A.J., Daha, M.R. and Roos, A., Induction of apoptosis by

the terminal sequence of complement (49) 95 Navratil, J.S., Zurowski, N. and Aheam, J.M., Apoptotic endothe-

lial cells and PBMC are tagged specifically by C3- and C4- derived ligands during membrane loss of RCA proteins: implications for immune tolerance and the pathogenesis of SLE (49) 36

Navratil, J.S., see Zurowski, N. (49) 36 Neal, J.W., see Mead, R.J. (49) 7 Neri, S., see Amodeo, G. (49) 61 Nicholson-Weller, A., see Ghiran, I. (49) 3 Nicholson-Weller, A., see Ghiran, I. (49) 86


Nicholson-Weller, A., see Tyagi, S.R. (49) 4 Nicholson-Weller, A., see Vincent, J.A. (49) 90 Niculescu, F., Soane, L., Badea, T., Shin, M.L. and Rus, H.,

Activation of STAT3 by sublytic C5b-9 in human aortic endothelial cells induces cell cycle (49) 93

Niculescu, F., see Hila, S. (49) 16 Niculescu, F., see Soane, L. (491 16 Niculescu, F., see Badea, T. (49) 93 Nielsen, C.H., Graham, R., Leslie, Q., Kaveri, S., Fischer, E. and

Kazatchkine, M.D., Natural autoantibodies and complement mediate B cell uptake of self antigens and their presentation to T cells (49) 49

Nielsen, C.H., see Leslie, R.G.Q. (49) 24 Niemerovsky, V.S., see Galebskaya, L.V. (49) 23 Niessen, H.W.M., see Hack, C.E. (49) 7 Nijmeijer, R., see Hack, C.E. (49) 7 Nilsson, A.-K., see Persson, L. (49) 20 Nilsson, B., see Ekdahl, K.N. (49) 90 Nilsson, E.B., see Andersson, J. (49) 96 Nilsson, K., see Andersson, J. (49) 96 Nishikawa, K., see Mizuno, M. (49) 63 Nonaka, M., Wang, G., Okada, H. and Nonaka, M., Significant

expression of guinea pig C4b-binding protein a-chain in epi- didymis by alternative promoter usage (49) 97

Nonaka, M., see Miyazawa, S. (491 3 Nonaka, M., see Suzuki, M. (49) 3 Nonaka, M., see Ji, X. (49) 43 Nonaka, M., see Nonaka, M. (49) 97 Noris, M., see Caprioli, J. (49) 13 Norsworthy, P.J., Fossati-Jimack, L., Taylor, P.R., Bygraves,

A.E., Walport, M.J. and Botto, M., Targeted disruption of the murine phagocytic receptor ClqRp and phenotypic analysis (491 36

Nosce, R., see Zurowski, N. (49) 36

Ocana-Morgner, C. and Dankert, J.R., Phenotypic induction of sensitivity to complement in complement-resistant Es- cherichia coli (49) 72

Ogden, C.A., Ghebrehiwet, B., Fadok, V. and Henson, P., Clq mediates the clearance of apoptotic cells (49) 40

Ohi, H., see Endo, M. (491 86 Ohsawa, I., see Endo, M. (49) 86 Ohta, R., see Miwa, T. (49) 25 Okada, H., see Miwa, T. (49) 25 Okada, H., see Miwa, T. (49) 65 Okada, H., see Miwa, T. (49) 92 Okada, H., see Abe, M. (49) 26 Okada, H., see Mizuno, M. (49) 63 Okada, H., see Okada, N. (49) 71 Okada, H., see Nonaka, M. (49) 97 Okada, M. and Hitsumoto, Y., Inhibition of human complement

activity by human fibronectin-containing fraction (49) 70 Okada, M., see Hitsumoto, Y. (49) 70 Okada, N., Wu, X., Yuki, Y. and Okada, H., Anti-GM2-IgM

antibody in fresh human serum induces cytolysis to HIV-1 infected cells (49) 71

Okada, N., see Mizuno, M. (491 63 Okada, N., see Miwa, T. (49) 65 Okada, N., see Miwa, T. (49) 92 Oldroyd, R.G., see Dodd, I. (49) 63 Olsson, L., see Ekdahl, K.N. (49) 90 Oppermann, M., see Settmacher, B. (49) 89 Orisio, S., see Caprioli, J. (49) 13 Ormsby, R.J., Male, D.A., Giannakis, E. and Gordon, D.L.,

Transcriptional regulation of Factor H-related genes (49) 45 Ormsby, R.J., see Male, D.A. (49) 45 Ormsby, R.J., see Giant&is, E. (49) 57 Ormsby, R.J., see Giant&is, E. (49) 66 Osaka, K., see Nakao, M. (49) 11 Overduin, M., see Guthridge, J. (49) 46

Palmarini, G., see Fonseca, MI. (49) 17 Palombo, G., see Amodeo, G. (49) 24 Pan, Q., Ebanks, R.O. and Isenman, D.E., Two clusters of acidic

amino acids near the NH*-terminus of C4 &chain are important for C2 binding (49) 54

Pangbum, M.K., Structure and function of factor H: mechanism of innate recognition of host and targets in the alternative pathway of complement (49) 57

Pangburn, M.K., see Rawal, N. (49) 4 Pangbum, M.K., see Ram, S. (49) 58 Papadimitriou, J.C., see Mastellos, D. (49) 8 Parent, J.B., Benzing, WC., Gupta-Bansal, R., Convery, M.,

Anderson, R. and Brunden, K.R., Efficacy of an anti-properdin MoAb in two models of complement-mediated tissue injury (49) 68

Parent, J.B., see Gupta-Bansal, R. (491 68 Parhar, R., see Kotwal, G.J. (49) 76 Park, M. and Tenner, A.J., Glycosylation stabilizes cell surface

expression of ClqRp (49) 40 Parker, C.J., see Kim, K.-C. (49) 93 Parker, J., see Lassiter, H. (491 22 Parker, K.P., see Koppenheffer, T.L. (49) 94 Parkinson, J., see Liszewski, M.K. (49) 54 Parkinson, J., see Kotwal, G.J. (49) 76 Pastor, C., Vidarte, L., Mas, S., Guerrero, R., Blazquez, A.B. and

Vivanco, F., Molecular characterization of the covalent complexes of C3b with the Fc region of human IgG (49) 96

Pastor, C., see Vidarte, L. (491 40 Paul, D., see Andra, J. (491 94 Paul, E., Mandik-Nayak, L., Erikson, J. and Carroll, M.C., Disrug

tion of B cell tolerance in C4-/ anti-DNA transgenic mice (49) 42

Paul, E., see Pozdnyakova, 0.0. (49) 79 Pausa, M., see Casarsa, C. (49) 17 Pavelka, M., see Hess, M.W. (49) 49 Pekna, M., see Persson, L. (49) 20 Peng, C., see Fung, M. (49) 68 Penn, U., see Friedman, H.M. (49) 58 Perdikoulis, M.V., see Reid, K.B.M. (49) 17 Perez-Caballero, D., see Sanchez-Corral, P. (49) 45


Perez de la Lastra, J.M., Harris, CL., Hinchliffe, S.J., Holt, D.S., Rushmere, N.K. and Morgan, B.P., Pigs express multiple forms of decay accelerating factor (CD55), all of which contain only three short consensus repeats (SCR) (49) 65

Perez de la Lastra, J.M., see Spiller, O.B. (49) 71 Perkins, S.J., see Hinshelwood, J. (49) 32 Perkins, S.J., see Hinshelwood, J. (49) 42 Perkins, S.J., see Guthridge, J. (49) 46 Perkins, S.J., see Guthridge, J. (49) 69 Perrin-Cocon, L.A., see Villiers, C.L. (49) 48 Persson, L., Nilsson, A.-K., Hietala, A. and Pekna, M., The role

of the complement system in the pathogenesis of atherosclero- sis in mice (49) 20

Pestel, S., see Schlaf, G. (49) 48 Petersen, S.V., Thiel, S., Vorup-Jensen, T., Jensen, L. and Jense-

nius, J.C., Control of the MBL pathway of complement activation (49) 83

Petersen, S.V., see Dahl, M.R. (49) 79 Petersen, S.V., see Liu, H. (49) 84 Petry, F., Botto, M., Walport, M.J. and Loos, M., Reconstitution

of the complement (Cl function in Clq deficient (Clqa-/-I mice with wild type bone marrow cells (49) 79

Petry, F., see Schwaeble, W.J. (49) 15 Pfaller, K., see Hess, M.W. (49) 49 Pickering, M.C., Fischer, S., Cooke, H.T., Walport, M.J. and

Botto, M., UVB-induced keratinocyte apoptosis in Clq deficient mice (49) 18

Pierangeli, S.S., see Myones, B.L. (49) 97 Piliero, L. and Sullivan, K., Opsonized immune complexes stimu-

late the production of TNFo from macrophages (49) 18 Pinkston, K., see Fung, M. (49) 68 Polizello, A.C.M., see Marzocchi-Machado, C.M. (49) 90 Ponti, A., see Bergamaschini, L. (49) 23 Post, C., see Schwaeble, W.J. (49) 15 Poulsen, K., see Vorup-Jensen, T. (49) 86 Poutanen, K., see Jaatinen, T. (49) 43 Powell, R., see Spiller, O.B. (49) 67 Powell, S., see Dodd, I. (49) 63 Pozdnyakova, O.O., Barrington, R.A. and Carroll, M.C., Follicu-

lar dendritic cells @DC’s) found in bone marrow (BM) are associated with B lymphocytes (491 50

Pozdnyakova, O.O., Paul, E., Schneider, T.J. and Carroll, M.C., C4- and CD2 1 /CD35deficiency predisposes mice to sponta- neous autoreactivity (491 79

Pozdnyakova, O.O., see Barrington, R.A. (49) 37 Prada, A., see Zahedi, K. (49141 Pratt, J.R., Basheer, S. and Sacks, S.H., Abrogation of acute

transplant rejection in the absence of locally synthesised C3 (49) 23

Pratt, J.R., Dong, J., Sacks, S.H. and Smith, R.A.G., Engineering donor organs by perfusion with membrane-targeted biophar- maceuticals: in situ blockade of reperfusion-associated complement activation in experimental renal transplantation (49) 8

Pratt, J.R., see Dodd, I. (49) 63 Prieur, A., see Dragon-Durey, M.A. (49) 25 Prodinger, W.M., see Hess, M.W. (49) 49 Prodinger, W.M., see Kacani, L. (49) 72

Qian, Y.M., Qin, X., Miwa, T., Sun, X., Halperin, J.A. and Song, W.C., Identification and functional characterization of a new gene encoding the mouse terminal complement inhibitor CD59 (49) 50

Qin, X., see Qian, Y.M. (49) 50 Quartier, P., see Dragon-Durey, M.A. (49) 25 Quigg, R., see Kang, H.J. (49) 49 Quigg, R.J., see Alexander, J.J. (49) 49

Ragnauth, C., see Dodd, I. (49) 63 Rakstang, J., see Guthridge, J. (49) 46 Ram, S., Cullinane, M., Gulati, S., Blom, A., Dahlback, B.,

Elkins, C., Pangburn, M.K., McQuillen, D.P., Monks, B.G. and Rice, P.A., Stable serum resistance of Neisseria gonorrhoeae is mediated by binding of C4b-binding protein to gonococcal porin (49) 58

Ram, S., Mackinnon, F.G., Gulati, S., Vogel, U., Gorringe, A. and Rice, P.A., The molecular basis of group B meningococcal serum resistance (49) 73

Ram, S., Vogel, U., Gulati, S., Heinze, G., Van der Ley, P., Frosch, M. and Rice, P.A., Complement-group B meningococcal interactions: a study using isogenic mutant strains (49) 73

Ranganathan, S., see Male, D.A. (49) 45 Ranganathan, S., see Giannakis, E. (49) 57 Raschke, U., see Grove, M. (49) 25 Rawal, N. and Pangbum, M.K., High affinity C5 convertases of

the alternative pathway of complement (491 4 Regal, J.F., Larsen, C.P. and Kane, T.M., Complement activation

by the occupational allergen trimellitic anhydride (TMA) (49) 26

Rehrig, S.T., see Fleming, S.D. (491 22 Rehrig, ST., see Fleming, S.D. (49) 37 Reid, K.B.M., Strong, P., Perdikoulis, M.V. and Kishore, U.,

Expression and binding properties of the homotrimeric forms of the globular regions of the A-, B- and C-chains of C lq (49) 17

Reid, K.B.M., see Kojouharova, MS. (49) 40 Reiman, R., see Campos-Tortes, A. (49) 48 Reinhardt, R., see Sanderson, S. (49) 96 Remuzzi, G., see Caprioli, J. (49) 13 Rennebohm, R.M., see Yung Yu, C. (49) 32 Reveille, J., see Moulds, J.M. (49) 29 Reveille, J., see Rupert, K.L. (49) 29 Rheinheimer, C., see Settmacher, B. (49) 89 Rice, P.A., see Ram, S. (49) 58 Rice, P.A., see Ram, S. (49) 73 Richards, A., see Fecke, W. (49) 91 Richardson, B.A., see Soulika, A.M. (49) 62 Rieben, R., Dzelalija, K. and Mohacsi, P., Complement inhibitors

to prevent (hyper)-acute vascular rejection: in vitro and in vivo results with IgM-enriched IVIG, CIINH, and 5,000 d dextran sulfate (49) 7 1

Rieben, R., see Walpen, A. (491 91 Riela, A., see Amodeo, G. (49) 61 Riley, R.C., see Kemper, C. (49) 66 Ritsema, D.F., see Marchbank, K.J. (49) 47


Rivolta, E., see Carugati, A. (491 27 Roberts, S., see Moulds, J.M. (49) 29 Robson, M.G., Cook, H.T., Botto, M., Walport, M.J. and Davies,

K.A., Delayed resolution of inflammation in heterologous nephrotoxic nephritis in Clq deficient mice (49) 27

Robson, M.G., Cook, H.T., Taylor, P., Botto, M., Walport, M.J. and Davies, K.A., Accelerated nephrotoxic nephritis: increased severity of disease in C Iq deficient mice (49) 28

Rodriguez de Cbrdoba, S., see Sanchez-Corral, P. (49) 45 Rollins, S.A., Therapeutic intervention in acute and chronic dis-

ease with anti-C5 therapy (49) 69 Rolstad, B., see Lovik, G. (49) 41 Roos, A., Essers, M., Van Gijlswijk-Janssen, D.J., Bovin, N.V.

and Daha, M.R., Both IgG and IgM anti-pig antibodies induce complement activation and cytotoxicity (49) 18

Roos, A., Van Gijlswijk-Janssen, D.J., Faber-Krol, R. and Daha, M.R., Interaction of mannan-binding lectin with IgA (49) 83

Roos, A., see Nauta, A.J. (49) 95 Rose, D.R., see Van den Elsen, J.M.H. (49) 32 Rosenberg, J., see Harjunp%, A. (49) 20 Rossi, E., see Bergamaschini, L. (49) 23 Rossi, V., Bally, I., Thielens, N. and Arlaud, G.J., Functional

topology of the catalytic region of human Cls: insights into the molecular determinants of Cls specificity (49) 17

Rossi, V., see Gaboriaud, C. (49) 33 Rossi, V., see Thielens, N. (49) 87 Rothetmel, E., see Schlaf, G. (49) 48 Rowling, P.J.E., see Dodd, I. (49) 63 Rupert, K.L., Moulds, J.M., Yang, Y., Warren, R., Reveille, J.,

Amett, F.C. and Yung Yu, C., Molecular basis of complete C4 deficiency in a SLE patient with four mutant genes: a 2-bp insertion at exon 29 in C4A and a 1-bp deletion at exon 13 in C4B (49) 29

Rupert, K.L., see Yung Yu, C. (49) 32 Rus, H., see Soane, L. (49) 16 Rus, H., see Badea, T. (49) 93 Rus, H., see Niculescu, F. (49) 93 Rushmere, N.K., see Perez de la Lastra, J.M. (49) 65 Rushmere, N.K., see Holt, D.S. (49) 67 Russo, E.S.M., see Marzocchi-Machado, C.M. (49) 90 Rutz, R., see Garcia-Schiler, H. (49) 20 Ryan, J.C., see Lovik, G. (49) 41 Ryder, L.P., see Madsen, H.O. (49) 87 Ryumina, E.V., see Galebskaya, L.V. (49) 23

Saarinen-Pihkala, U., see Jaatinen, T. (49) 43 Sacks, S.H., see Pratt, J.R. (49) 8 Sacks, S.H., see Pratt, J.R. (49) 23 Sacks, S.H., see Dodd, I. (49) 63 Sagara, I., see Moulds, J.M. (49) 73 Sahu, A., Soulika, A., Morikis, D., Spruce, L., Moore, W.T. and

Lambris, J.D., Kinetics and proposed mechanism of binding of the complement inhibitor Compstatin (49) 53

Sahu, A., see Franchini, S. (49) 13 Sahu, A., see Zarkadis, I.K. (49) 13 Sahu, A., see Mollnes, T.E. (49) 62 Sahu, A., see Soulika, A.M. (49) 62

Saifuddin, M., see Spear, G.T. (49) 87 Sainz, I., see Cugno, M. (49) 62 Sakari Jokiranta, T., Hellwage, J., Friese, M., Zipfel, P.F. and

Meri, S., Identification of the binding site on Factor H SCR20 for C3d (49) 44

Sakari Jokiranta, T., Hellwage, J., Male, D.A., Giannakis, E., Zipfel, P.F., Meri, S. and Gordon, D.L., Comparison of the Factor H heparin binding sites on SCR domains 7 and 20 (49) 54

Sakari Jokiranta, T., see Meri, T. (49) 57 Sakata, N., see Abe, M. (49) 26 Saldanha, C., see Friedman, H.M. (491 58 Salmon, J.E., see Holers, V.M. (49) 8 Salvati, P., see Schwaeble, W.J. (491 15 Sanchez-Corral, P., Perez-Caballero, D., Gallardo, E., Gonzalez-

Rubio, C., L6pez-Trascasa, M. and Rodrfguez de C6rdoba, S., Genomic organization and mutational characterization of human factor H: Implications in hemolytic uremic syndrome (49) 45

Sanderson, S., Reinhardt, R. and Jackson, J., CSa-mediated re- lease of IL-6 from C5A receptor-bearing human osteoblasts (491 96

Sanderson, S.D., see Chronopoulou, E. (49) 89 Sarau, H.M., see Ames, R.S. (49) 53 Sarma, V., see Huber-Lang, M. (49) 47 Sarrias, M.R., see Guthridge, J. (49) 46 Sarrias, M.R., see Guthridge, J. (49) 69 Sasaki, M., see Ji, X. (49) 43 Sasaki, N., see Younger, J.G. (49) 22 Sasaki, S., see Ember, J.A. (49) 91 Satoh, N., see Suzuki, M. (49) 3 Satomura, A., see Endo, M. (49) 86 Savay, S., see Szebeni, J. (49) 71 Savill, J., see Botto, M. (49) 36 Scalia, R., see Song, W.C. (49) 24 Schafer, M.K.-H., see Schwaeble, W.J. (49) 15 Schieferdecker, H.L., Koleva, M., Schlaf, G., Giitze, 0. and

Jungerrnann, K., Expression of functional anaphylatoxin C5a receptors on hepatocytes after in-uiuo treatment of rats with IL-6 as demonstrated by direct CSa-dependent glucose output (4914

Schieferdecker, H.L., see Schlaf, G. (49) 48 Schlaf, G., Schieferdecker, H.L., Rothermel, E., Pestel, S., Junger-

mann, K. and G&e, O., Expression and metabolic function of anaphylatoxin C5a receptors on Kupffer cells, stellate cells and sinusoidal endothelial cells but not on hepatocytes of normal rat liver (49) 48

Schlaf, G., see Schieferdecker, H.L. (49) 4 Schneider, T.J., see Pozdnyakova, 0.0. (49) 79 Schoels, M., see Wagner, C. (49) 47 Schraufstatter, I., see DiScipio, R.G. (49) 93 Schrock, M., see Feldhoff, P. (49) 44 Schroeder Jr., H.W., see Xu, Y. (49) 80 Schwaeble, W., see Vorup-Jensen, T. (49) 86 Schwaeble, W.J., Schafer, M.K.-H., Post, C., Salvati, P., Cal-

abresi, M., Sim, R.B., Petty, F., Loos, M. and Weihe, E., Complement Clq is dramatically upregulated in brain mi-


croglia in response to transient global cerebral &hernia (49) 15

Schwaeble, W.J., Stover, C.M., Hanson, S., Weiss, E.H. and Sim, R.B., Genomic organisation of the human complement regulatory component factor H (491 13

Schwaeble, W.J., see Stover, CM. (49) 86 Schwendinger, M.G., see Hess, M.W. (49) 49 Schwendinger, M.G., see Kacani, L. (49) 72 Seilly, D.J., see Femie-King, B.A. (49) 74 Sekine, H., Colten, H., Gamier, G., Circolo, A. and Gilkeson, G.,

Complement factor C3 is not required for full expression of lupus nephritis in MRL/lpr mice (49) 28

Selander, B., Kiyhty, H., Wedege, E., Holmstriim, E., Truedsson, L., Siiderstrom, C. and Sjoholm, A.G., Vaccination responses to Neisseria meningitidis and Haemophilus injluenzae type b in two C2-deficient sisters (49) 74

Settmacher, B., Rheinheimer, C., Oppermann, M., Hamacher, H., Bock, D., Kdhl, J., Bautsch, W. and Klos, A., Stmcture/function analysis of the C3A-receptor C-terminus (491 89

Settmacher, B., see Ames, R.S. (49) 53 Sfyroera, G., see Franchini, S. (49) 13 Sharma, M., see Ayub, S. (491 48 Shea-Donohue, T., see Fleming, S.D. (491 22 Shea-Donohue, T., see Fleming, S.D. (491 37 Shen, X.-P., see Birmingham, D.J. (49) 29 Shen, Y., see Wang, Y. (49) 19 Shi, L., see Chronopoulou, E. (49) 89 Shi, L., see Ember, J.A. (49) 91 Shibata, K., see Abe, M. (49) 26 Shih, C.C.-Y., see Chronopoulou, E. (49) 89 Shih, C.C.-Y., see Ember, J.A. (49) 91 Shimizu, N., see Abe, M. (49) 26 Shin, M., see Hafer-Macko, C. (49) 16 Shin, M.L., see Soane, L. (49) 16 Shin, M.L., see Badea, T. (491 93 Shin, M.L., see Niculescu, F. (491 93 Sim, D.S., Thiel, S. and Devine, D.V., C4b-binding protein and

mannose binding lectin interactions with B2-glycoprotein I: association of complement activation and antiphospholipid antibodies (49) 83

Sim, R.B., see Schwaeble, W.J. (491 13 Sim, R.B., see Schwaeble, W.J. (491 15 Sim, R.B., see Laich, A. (49) 42 Sim, R.B., see Irigoin, F. (491 75 Sim, R.B., see Kojima, M. (49) 88 Sinden, R.E., see Margos, G. (491 73 Singhrao, S., see Mead, R.J. (491 7 Sivasankar, B., see Ayub, S. (49) 48 Sivasankar, B., Tiwari, S.C., Srivastava, L.M. and Das, N., Ex-

pression of plasma soluble CR1 and leukocyte surface CR1 in patients with glomerulonephritis (49) 28

Sjiiholm, A.G., see Selander, B. (491 74 Skerka, C., see Kraiczy, P. (49) 57 Smith, B.O., Uhrin, D., Krych-Goldberg, M., Wang, X., Atkinson,

J.P. and Barlow, P.N., Solution structure of complement control protein (CCP) modules 15 and 16 of CR1 - interpretation of mutagenesis experiments (49) 46

Smith, B.O., see Mallin, R. (49) 46 Smith, G.P., Dodd, I., Davies, A., Morgan, B.P., Lachmann, P.J.

and Smith, R.A.G., Derivatization of soluble human CD59 with a myristoylated peptide creates a potent membrane-bound inhibitor of complement-mediated lysis (49) 53

Smith, G.P., see Dodd, I. (491 63 Smith, K., see Harrison, R. (49) 63 Smith, R.A.G., see Pratt, J.R. (49) 8 Smith, R.A.G., see Smith, G.P. (491 53 Smith, R.A.G., see Dodd, I. (49) 63 Smith, S., see Kotwal, G.J. (491 76 Soane, L., Cho, H., Niculescu, F., Rus, H. and Shin, M.L.,

Sublytic C5b-9 promotes OLG survival through inhibition of mitochondrial pathway of apoptosis (49) 16

Soane, L., see Badea, T. (49) 93 Soane, L., see Niculescu, F. (49) 93 Soderstrdm, C., see Selander, B. (49) 74 Soin, B., see Harrison, R. (49) 63 Song, S., see Chronopoulou, E. (49) 89 Song, W.C., Scalia, R., Miwa, T., Lambris, J.A. and Lefer, A.M.,

Deficiency of decay-accelerating factor (DAF) attenuates leukocyte-endothelium interaction induced by hemorrhage and reinfusion (49) 24

Song, W.C., see Miwa, T. (49) 25 Song, W.C., see Qian, Y.M. (49) 50 Songer, J.G., see Tambourgi, D.V. (491 19 Sorensen, ES., see Vorup-Jensen, T. (491 86 Soulika, A., see Sahu, A. (49) 53 Soulika, A.M., Khan, M.M., Hattori, T., Bowen, F.W., Richard-

son, B.A., Hack, C.E., Sahu, A., Edmunds Jr., L.H. and Lambris, J.D., Inhibition of heparin/protamine complex-induced complement activation by Compstatin in baboons (49) 62

Spear, G.T., Hart, M.L., Saifuddin, M., Zhang, Y., Xu, B. and Gewurz, H., Interaction of HIV-l with mannose binding lectin (49) 87

Spencer, D.I.R., see Hinshelwood, J. (491 32 Spiegelman, B.M., see Xu, Y. (49) 80 Spiller, O.B., Goodfellow, I., Harris, CL., Perez de la Lastra,

J.M., Evans, D. and Morgan, B.P., Echovirus and Coxsackie B viruses that bind human CD55 are unable to use porcine CD55 as a receptor (49) 71

Spiller, O.B., Goodfellow, I., Powell, R., Evans, D. and Morgan, B.P., Echovirus-infected cells are resistant to complement- mediated lysis despite direct binding of CD55 and down-regulation of remaining complement regulators (49) 67

Spiller, O.B., see Harris, C.L. (49) 64 Sptinzl, G.M., see Kacani, L. (49) 72 Spruce, L., see Sahu, A. (49) 53 Sriramarao, P., see DiScipio, R.G. (49) 93 Srisatjaluk, R., see Kotwal, G.J. (49) 76 Srivastava, L.M., see Arora, M. (49) 28 Srivastava, L.M., see Sivasankar, B. (49) 28 Stahl, G.L., see Montalto, M.C. (491 19 Stahl, G.L., see Jordan, J.E. (49) 24 Stahl, G.L., see Zhao, H. (49) 83 Stahl, G.L., see Collard, C.D. (49) 85


Stall, A., see Chronopoulou, E. (49) 89 Stall, A., see Ember, J.A. (49) 91 Stammler, P., see Lutz, H.U. (49) 67 Stapp, J., see Feldhoff, P. (49) 44 Stegmaier, S., see Wagner, C. (49) 47 Steindl, F., see Kacani, L. (49) 72 Stoiber, H., see Kacani, L. (49) 72 Stover, CM. and Schwaeble, W.J., Organization of the human

and murine MASP-2 gene cluster (49) 86 Stover, CM., see Schwaeble, W.J. (49) 13 Strong, P., see Reid, K.B.M. (49) 17 Sugamura, K., see Takahashi, M. (49) 3 Sullivan, K., see Piliero, L. (49) 18 Sullivan, K.E., A new transcription factor involved in the tran-

scriptional regulation of early complement components (49) 11

Sulpizio, A.C., see Ames, R.S. (49) 53 Sun, C., see Fung, M. (49) 68 Sun, W.N., see Fung, M. (49) 68 Sun, X., see Miwa, T. (49) 25 Sun, X., see Qian, Y.M. (49) 50 Suzuki, M., Satoh, N. and Nonaka, M., Cytolytic complement

system in invertebrates suggested by EST analysis of am- phioxus notochord (49) 3

Svejgaard, A., see Madsen, H.O. (49) 87 Syfroera, G., see Zarkadis, I.K. (49) 13 Szalai, A.J., see Xu, Y. (49) 80 Szebeni, J., Baranyi, L., Savay, S., Chanan-Khan, A.A., Klein, P.,

Koenig, K., Muggia, F.M., Barenholz, Y., Danino, D., Tal- mon, Y. and Alving, C.R., Hypersensitivity to Taxol and Doxil: experimental and clinical evidence for a causal role of complement activation (49) 71

Szillgyi, K., see Zavodszky, P. (49) 89 Szpirer, C., see Lovik, G. (49) 41

Tack, B.F., see Drouin, S.M. (49) 26 Tacnet, P., Galvan, M., Chevallier, S., Glabe, C., Tenner, A.J. and

Arlaud, G.J., Cl activation by amyloid B fibrils. Evidence for a binding site for AB on the Clq globular regions (49) 16

Takahashi, K., see Liu, H. (49) 84 Takahashi, K., see Vorup-Jensen, T. (49) 86 Takahashi, K., see Kuipers, S. (49) 87 Takahashi, K., see Xu, B. (49) 88 Takahashi, M., Miura, S., Ishii, N., Matsushita, M., Endo, Y.,

Sugamura, K. and Fujital, T., An essential role of MASP-1 in activation of the lectin pathway (49) 3

Takahashi, M., see Kenjo, A. (49) 84 Talmon, Y., see Szebeni, J. (49) 71 Tambourgi, D.V., De Sousa, M., Billington, S.J., Songer, J.G. and

Van den Berg, C.W., C-susceptibility of erythrocytes induced by spider and bacterial phospholipases is due to loss of membrane assymetry (49) 19

Tambourgi, D.V., see Van den Berg, C.W. (49) 95 Tanaka, N., see Nakao, M. (49) 12 Taylor, P., see Robson, M.G. (49) 28 Taylor, P.R., see Botto, M. (49) 36

Taylor, P.R., see Norsworthy, P.J. (49) 36 Tchorbadjieva, ML, see Kojouharova, M.S. (49) 40 Tedesco, F., see Casarsa, C. (49) 17 Tenner, A.J., see Webster, S.D. (49) 15 Tenner, A.J., see Tacnet, P. (49) 16 Tenner, A.J., see Fonseca, M.I. (49) 17 Tenner, A.J., see Park, M. (49) 40 Tenner, A.J., see Jack, D.L. (49) 88 Test, S.T., Mitsuyoshi, J., Connolly, C.C. and Lucas, A.H., Con-

jugation of complement C3d enhances the antibody response to pneumococcal serotype 14 capsular polysaccharide (49) 44

Tew, M., see Moulds, J.M. (49) 29 Thiel, S., Anker Peterslund, N., Koch, C. and Chr. Jensenius, J.,

Plasma level of mannan-binding lectin (MBL) as predictor of sepsis after chemotherapy (49) 85

Thiel, S., see Jensenius, J.C. (49) 33 Thiel, S., see Dahl, M.R. (49) 79 Thiel, S., see Petersen, S.V. (49) 83 Thiel, S., see Sim, D.S. (49) 83 Thiel, S., see Erdei, A. (49) 84 Thiel, S., see Liu, H. (49) 84 Thiel, S., see Vorup-Jensen, T. (49) 86 Thiel, S., see Thielens, N. (49) 87 Thiel, S., see Gadjeva, M. (49) 89 Thielens, N., Cseh, S., Thiel, S., Rossi, V., Jensenius, J.C. and

Arlaud, G.J., Expression and characterization of the MApl9 component of the MBL pathway of complement (49) 87

Thielens, N., see Rossi, V. (49) 17 Thielens, N., see Erdei, A. (49) 84 Thiru, S., see Harrison, R. (49) 63 Thorley, B., see Loveland, B.E. (49) 66 Till, G.O., see Younger, J.G. (49) 22 Tiwari, S.C., see Sivasankar, B. (49) 28 Tometta, M.A., see Ames, R.S. (49) 53 Totsuka, S., see Nakao, M. (49) 12 Trofimov, A., see Zhakhov, A. (49) 72 Truedsson, L., see Selander, B. (49) 74 Tsokos, G.C., see Fleming, SD. (49) 22 Tsokos, G.C., see Fleming, S.D. (49) 37 Tsonis, P.A., see Mastellos, D. (49) 8 Turner, M.W., see Jack, D.L. (49) 88 Tyagi, S.R., Klickstein, L.B. and Nicholson-Weller, A., C5a-

stimulated human neutrophils utilize CR3, but not LFA-1 to support the adhesion-dependent phase of superoxide production (49) 4

Tzacheva, LG., see Kojouharova, M.S. (49) 40

Uemura, K., see Kawasaki, T. (49) 85 Uhrin, D., see Mallin, R. (49) 46 Uhrin, D., see Smith, B.O. (49) 46 Ulgiati, D., Virasch, N. and Holers, V.M., Characterization of the

CR2/CD21 proximal promoter: functional role for APl/AP2 sites and two adjacent Ebox motifs (49) 14

Ulgiati, D., see Holers, V.M. (49) 47 Undar, A., see Fung, M. (49) 68 Ursu, S., see Zurowski, N. (49) 36


Vaage, J.T., see Lovik, G. (49) 41 Van den Berg, C., see McGreal, E.P. (49) 7 Van den Berg, C.W. and Capey, S., Transfer of GPI-anchored

CD59 requires cell to cell contact (49) 92 Van den Berg, C.W., De Andrade, R.M.G., Magnoli, F.C. and

Tambourgi, D.V., Loxosceles spider venom induces cleavage of MCP/CD46 and increases C-resistance by activation of metalloproteinases (49) 95

Van den Berg, C.W., see Tambourgi, D.V. (491 19 Van den Elsen, J.M.H., Martin, A., Wong, V.B., Rose, D.R. and

Isenman, D.E., X-ray crystal structure of the C4d fragment of human C4A (49) 32

Van der Ley, P., see Ram, S. (49) 73 Van Dijk, H., see Harmsen, T. (491 21 Van Dijk, H., see Kuipers, S. (49) 87 Van Gijlswijk-Janssen, D.J., see Roos, A. (49) 18 Van Gijlswijk-Janssen, D.J., see Roos, A. (49) 83 Vasile, B., see Caprioli, J. (49) 13 Vaughn, W., see Fung, M. (49) 68 Vecchi, M., see Cugno, M. (49) 62 Verevochkin, S., see Zhakhov, A. (49) 72 Verschoor, A., Brockman, M.A., Knipe, D.M. and Carroll, M.C.,

Local synthesis of C3 in lymphoid tissues is sufficient to restore humoral responses to peripheral herpes simplex virus (HSV-1) infection in C3-deficient mice (49) 72

Vial, C., see Harrison, R. (49) 63 Vidarte, L., Pastor, C., Mas, S., Guerrero, R., Blazquez, A.B. and

Vivanco, F., Identification of the CHl residue involved in the C3b covalent binding to human IgG (49) 40

Vidarte, L., see Pastor, C. (49) 96 Videm, V., see Mollnes, T.E. (49) 62 Villiers, C.L., Perrin-Cocon, L.A., Chesne, S. and Marche, P.N.,

Antigen targeting by complement receptors (49) 48 Villoutreix, B.O., see Blom, A.M. (49) 74 Villoutreix, B.O., see Webb, J.H. (49) 96 Vincent, J.A., Lacouture, M.E., Nicholson-Weller, A. and Klick-

stein, L.B., An in vitro, complement-dependent model of particle transfer from erythrocytes to macrophages (49) 90

Virasch, N., see Ulgiati, D. (49) 14 Visser, CA., see Hack, C.E. (491 7 Vivanco, F., see Vidarte, L. (49) 40 Vivanco, F., see Pastor, C. (49) 96 Vogel, C.-W., see Bammert, H. (49) 12 Vogel, C.-W., see Andra, J. (49) 94 Vogel, C.-W., see Wehrhahn, D. (49) 94 Vogel, H., Halme, J. and Kirschfink, M., Expression of soluble

and membrane-bound complement regulatory proteins by human hepatocytes (49) 63

Vogel, U., see Ram, S. (49) 73 Vogel, U., see Jack, D.L. (491 88 Volanakis, J.E., see Xu, Y. (49) 80 Vorup-Jensen, T., Sorensen, E.S., Jensen, U.B., Poulsen, K.,

Schwaeble, W., Kawasaki, T., Wakamiya, N., Jensen, T.G., Takahashi, K., Ezekowitz, R.A.B., Thiel, S. and Jensenius, J.C., Recombinant expression of human mannan-binding lectin (49) 86

Vorup-Jensen, T., see Dahl, M.R. (49) 79

Vorup-Jensen, T., see Petersen, S.V. (491 83 Vomp-Jensen, T., see Gadjeva, M. (49) 89 Vreeke, T.M., see Kim, K.-C. (49) 93

Wada, K., see Montalto, M.C. (49) 19 Wagner, C., Hlnsch, G.M., Stegmaier, S. and Schoels, M., The

complement receptor 3 (CR3) on T-lymphocytes: a regulatory molecule (49) 47

Wagner, E., Jiang, H. and Frank, M.M., Modulation of the alternative complement pathway by Cl inhibitor (CIINH) (49) 61

Wakamiya, N., see Vorup-Jensen, T. (49) 86 Walpen, A., Mohacsi, P. and Rieben, R., Lysis of rabbit erythro-

cytes by human serum requires anti-Gal antibody, the altema- tive complement pathway, and Clq (49) 91

Walport, M.J., see Mitchell, D.A. (49) 18 Walport, M.J., see Pickering, M.C. (49) 18 Walport, M.J., see Robson, M.G. (49) 27 Walport, M.J., see Robson, M.G. (49) 28 Walport, M.J., see Botto, M. (49) 36 Walport, M.J., see Norsworthy, P.J. (49) 36 Walport, M.J., see Holt, D.S. (49) 67 Walport, M.J., see Petty, F. (491 79 Wang, G., see Nonaka, M. (49) 97 Wang, L., see Friedman, H.M. (49) 58 Wang, X., see Mallin, R. (49) 46 Wang, X., see Smith, B.O. (49) 46 Wang, X.D., see Chronopoulou, E. (49) 89 Wang, Y., Kristan, J., Hao, L., Lenkoski, C.S., Shen, Y. and

Matis, L.A., A role for complement in antibody-mediated inflammation: C5 deficient DBA/ 1 mice are resistant to colla- gen-induced arthritis (491 19

Ward, P.A. and Huber-Lang, M., Harmful effects of CSA in experimental sepsis (491 23

Ward, P.A., see Younger, J.G. (491 22 Ward, P.A., see Huber-Lang, M. (49) 47 Warren, R., see Rupert, K.L. (49) 29 Watanabe, R., see Kinoshita, T. (491 92 Watson, C.C., see Marchbank, K.J. (49) 47 Webb, J.H., Villoutreix, B.O., Dahlback, B. and Blom, A.M.,

Localisation of the protein S binding site on the C4BP B-chain (49) 96

Webb, J.H., see Blom, A.M. (49) 74 Webster, S.D., Galvan, M.D. and Tenner, A.J., Clq enhances

antibody-mediated uptake of the amyloid B-peptide by mi- croglia (49) 15

Wedege, E., see Selander, B. (49) 74 Wehrhahn, D., Meiling, K.M., Fritzinger, D.C., Bredehorst, R.,

Andr’ii, J. and Vogel, C.-W., Analysis of the structure/function relationship of cobra venom factor (CVF) and C3: generation of CVF/cobra-C3 hybrid proteins (491 94

Weihe, E., see Schwaeble, W.J. (49) 15 Weis, J.H., see Zabel, M.D. (49) 32 Weiss, E.H., see Schwaeble, W.J. (49) 13 Weiss, L., see Dragon-Durey, M.A. (49) 25 Wetsel, R.A., see Matthews, K.W. (491 15 Wetsel, R.A., see Drouin. S.M. (49) 26


Wetsel, R.A., see Kildsgaard, J. (49) 80 White, D., see Harrison, R. (49) 63 Whoolery, K.L., see Montalto, M.C. (49) 19 Wiklund, T., see Harjunpla, A. (491 20 Williams, L., see Loveland, B.E. (49) 66 Willis, A.C., see Ciganda, M. (49) 74 Willis, A.C., see Dahl, M.R. (49) 79 Windman, S., see Ember, J.A. (491 91 Wong, V.B., see Van den Elsen, J.M.H. (49) 32 Wu, X., see Okada, N. (49) 71 Wlrzner, R., see Kraiczy, P. (49) 75

Xu, B., Zhang, Y., Takahashi, K., Ezekowitz, A.R., Lint, T.F. and Gewurz, H., Interactions between MBL and the MASP proteins in lectin pathway hemolysis (49) 88

Xu, B., see Spear, G.T. (49) 87 Xu, C., see Molina, H. (49) 80 Xu, Y., Ma, M., Ippolito, G.C., Johnson, R.S., Szalai, A.J.,

Spiegelman, B.M., Schroeder Jr., H.W., Carroll, M.C. and Volanakis, J.E., Activation of the alternative complement pathway in factor D-deficient mice (49) 80

Yang, L., see Zhang, M. (49) 50 Yang, Y., see Rupert, K.L. (49) 29 Yang, Z., see Yung Yu, C. (49) 32 Yano, T., see Nakao, M. (49) II Yano, T., see Nakao, M. (49) 12 Young, K., see Guthridge, J. (49) 46 Young, K., see Guthridge, J. (491 69 Younger, J.G., Sasaki, N., Till, G.O. and Ward, P.A., Role of

complement activation in circulatory collapse: studies with cobra venom factor hemorrhagic shock (491 22

Younkin, E., see Huber-Lang, M. (49) 47 Yu, J.X., Bradt, B.M. and Cooper, N.R., Molecular cloning of the

cDNA of the C6A form of the sixth component of murine complement: functional integrity despite the absence of factor I modules (FIMs) (49) 14

Yu, J.X., Bradt, B.M., Hsiao, K. and Cooper, N.R., Amyloid plaques in a transgenic mouse model of Alzheimer’s disease (AD) contain complement components and pro-inflammatory cytokines (49) 7

Yuki, Y., see Okada, N. (49) 71 Yung Yu, C., Blanchong, C.A., Zhou, B., Rupert, K.L., Yang, Z.,

Jones, K.N. and Rennebohm, R.M., The l-2-3 loci theory of human complement component C4: heterozygosity in gene size and gene number as a mechanism to maintain C4 genetic diversity in the population (49) 32

Yung Yu, C., see Rupert, K.L. (49) 29

Zabel, M.D. and Weis, J.H., Chromatin accessibility and factor binding capability of the murine CD21 gene (49) 32

Zafari, M., see Barrington, R.A. (49) 37 Zahedi, K., Prada, A., Mulligan, A. and Davis III, A.E., Multiple

mechanisms regulate Cl inhibitor (ClINH) induction by inter- feron-y (IFN-?I). (49) 41

Zahedi, R. and Davis III, A.E., Cl inhibitor (ClINH) target protease specificity (49) 61

Zanichelli, A., see GioffrC, D. (49) 27 Zarkadis, I.K., Syfroera, G., Franchini, S., Sahu, A. and Lambris,

J.D., Characterization of factor H-like molecules in rainbow trout (49) 13

Zarkadis, I.K., see Franchini, S. (49) 13 Zavodszky, P., Lorincz, Z., Cseh, S., Dob6, J., Szilagyi, K.,

Ambrus, G. and Gal, P., The cleavage of two Cls subunits by a single active Clr reveals substantial flexibility of the Cls- Clr-CIr-Cls tetramer in the Cl complex (49) 89

Zhakhov, A., Fontaine, M., Verevochkin, S., Trotimov, A., Gilbert, D. and Ischenko, A., Determination of the factor H in sera of HIV infected patients by anti-factor H monoclonal antibodies (49) 12

Zhang, M., Barrington, R.A., Yang, L. and Carroll, M.C., Regu- lated survival of activated B cells by complement receptors CD21 /CD35 (49) 50

Zhang, M., see Barrington, R.A. (49) 37 Zhang, Q., see Grove, M. (49) 25 Zhang, Y., see Spear, G.T. (49) 87 Zhang, Y., see XII, B. (491 88 Zhao, H. and Stahl, G.L., Characterization of monoclonal antibod-

ies (mAb) against native and recombinant human mannose-binding lectin (MBL) (491 83

Zhou, B., see Yung Yu, C. (49) 32 Ziegler, S., see Garcia-Schlller, H. (49) 20 Zimmerman, P., see Moulds, J.M. (49) 73 Zingale, L.C., see Carugati, A. (491 27 Zipfel, P.F., see Caprioli, J. (49) 13 Zipfel, P.F., see Sakari Jokiranta, T. (491 44 Zipfel, P.F., see Friese, M.A. (49) 45 Zipfel, P.F., see Sakari Jokiranta, T. (49) 54 Zipfel, P.F., see Kraiczy, P. (49) 57 Zipfel, P.F., see Meri, T. (491 57 Zipfel, P.F., see Hellwage, J. (491 70 Zou, J.-C., see Chronopoulou, E. (49) 89 Zurowski, N., Navratil, J.S., Ursu, S., Nosce, R. and Aheam,

J.M., Ultraviolet B (UVB) induces apoptosis and deposition of C3- and C4- derived ligands on primary human and murine keratinocytes in vivo: implications for immune tolerance and the pathogenesis of SLE (49) 36

Zurowski, N., see Navratil, J.S. (49) 36

Download - Author index of abstracts

Top Related